{"docstore/metadata": {"0bfc066a-ba86-40ed-8104-6d4beb6f2d85": {"doc_hash": "a13aa66291e3d87b4fec54be664d2dc79aeed74114559331571d71f932f807f8"}, "1107ab99-664b-48a5-b94f-ea9025bf18b8": {"doc_hash": "ce62fc0579a0142b8347bbdff219917ebaffb249f24a0735495e6cf1977dcc25"}, "a8717909-0907-4df6-b12a-c03d0343fd63": {"doc_hash": "efbc8660ff18057cd186140e798376898e7d18c573dc3f729c905727af7498f4"}, "cc38eaa8-ce72-49e3-b971-e7dc10b40b27": {"doc_hash": "f4659fe3b19f0fa75b1e555f8d93829ff4265e63fee849e183c3a4c8e914e4df"}, "892bb4b6-097f-4f5e-ac43-46cad64c9f8e": {"doc_hash": "e614cc6fd01d3449ce2a8b5509e84ea522f68eedd13b777918234717531cf303"}, "2b757389-852c-42b7-8b22-598cab104548": {"doc_hash": "b4e958ba7d8583e822cc698db14c59e8c7ba16cc7fb7466ed27ceea5f513c0a0"}, "f0dcae12-7262-4bd1-b26d-8949e0dd23ff": {"doc_hash": "18a907982bb59f068bc29476e7ca9a5d9c8460e6c2d6bb7d3a63b9e2eef6ff15"}, "4416187a-48b2-4ba2-ba33-967b7851d49c": {"doc_hash": "e16f48c20e0b3f9c44ceb73ee825173ed7ffa76df7adf2b9586bc02ae3c25cf0"}, "a7311867-ad05-4682-86c6-aa0979a2a0fd": {"doc_hash": "6490ca8fedaaa6dd71119c2d5b924af12a2506bd14bd344e85dfb762fe0feb5c"}, "103eab7d-0c6d-4ac8-86dc-b6efcbc69614": {"doc_hash": "232f10c9488a1bd94a8434e5758e0fa84b7f5ef5be4b8b8b9de5e8507c6252ac"}, "5133dbb4-b887-4acd-a401-e7625d9a4773": {"doc_hash": "716f35479b5e29f46b47208dd6a1b6825112816b1cdb5acc0156233c5a2f48fc"}, "e9add9a4-05a6-40de-8b34-253eabc8f98e": {"doc_hash": "45f92bf2e4b78bfe43150d25942159d06f896967ea1702a7c9caaec4b6a1edce"}, "b2f4a49f-f2bc-4159-9ed4-1ce70bf7a418": {"doc_hash": "80efad3847b8345d8ce0b6230dec0ae2907270cae52df14295c8e8239022ec50"}, "da442196-2381-49b8-90ce-0d40bfe337bf": {"doc_hash": "94c5c876d5c3ec2b6851a44d69499d1e3fcae647498915f64bc06c9f9c8e0c9e"}, "a116771d-514d-4b60-8024-d3503a4638ae": {"doc_hash": "274b0b185714710ffac7492ff7e2f7ef78142d97620a3dc39ec41b7c9fe6f8dd"}, "75ec51b9-be27-434e-b6df-d9f261ca2253": {"doc_hash": "22c361c4375ca6d14fb731dd04d0cb8c9cdcc2579bfcde51bc6a8ff346bb02a5"}, "076164f0-a19f-4bde-9daa-2d063ab87c93": {"doc_hash": "47076159d54109b0007a2833300a6bd6a5ba49b3450c170778284cd4532a6b9b"}, "ed305f47-a111-4fe0-a483-79212d988b65": {"doc_hash": "e0a85a67983686443ede4ed8eaef34d4f2ac71499cd47574f018556cf67a65d4"}, "9d035547-2b01-4fd6-936a-7a1f11fbb0c5": {"doc_hash": "3fe908e556e9c6d6544dceb016aa25cadb1ba3026bda4978a0f4b97838be644b"}, "c908c086-bda0-45ae-b975-e2a4e5192787": {"doc_hash": "b34fe60485672a6dbeb33669bf6332bcdbc573008c5c4610cd95f1c93521e265"}, "a9dbf832-4334-4668-ab56-7c9c889a92c0": {"doc_hash": "bee1a589ae99b0418c2581e8e62b2f27d40523ea66221c00b4cd27da1a7236b5"}, "2de40199-8596-47f5-8203-98e24286a7c7": {"doc_hash": "6c14fef4774e49a6d79a10be35f5e6841a15bcaecf186ad751f64f07c2a40e63"}, "595d2b25-1048-4cda-8533-b59b1768ec7c": {"doc_hash": "df69852708d82630e33ea6cc4b741cc2f2e074166692d5b2a9518c5885c5c1e2"}, "2abe2a1d-9183-4862-864a-f2fc074aed8d": {"doc_hash": "9b37b4f3145110da253512b2068d1d635bd8bb8884892ec4fd80c7a7f3a0d115"}, "f0d1f3f5-6bbf-43bb-a474-bbc09a4335bf": {"doc_hash": "677b31b2e4f3bf57a5ef5a428ad5ac86b1451a491da8d9e02dfabb6061d0bd9a"}, "9764b622-a0f5-455f-86b2-448bccb6f9c8": {"doc_hash": "28322e01d271e3224b1f99a9df76f1f96f8c74f0698dd8190f06e857b75c541b"}, "07168dc4-6b65-4ea3-bcba-263687653332": {"doc_hash": "3370e8af24ef82b8a520acf52dd256c08d8fd0186de4c043be6802260ae5c20b"}, "5adf154b-4e1e-40c6-9f46-002e60ddc559": {"doc_hash": "cde4b9758b508b9c91073d4ac397efa522c4d0d53acda4a8d6b552ed5b455bf5"}, "14061b51-3fd6-463c-9b1d-53a4e0bf6fb4": {"doc_hash": "cc180752e12c25a721cb47886e7d8b042beb551bd43c39c28f3550a91a68c3f5"}, "eaa8a52f-a714-4d3e-a134-1c2cc2e39422": {"doc_hash": "ba0d99a3293ca1ad549161c8dd94e7a3896434962581c0433e5f4b1b29f69222"}, "7b80ed4a-affa-4944-9bea-8d3cba483d10": {"doc_hash": "b72141b69eff4ad30bf47bf1d733e493035c586df4b68aa1fb53dd9a97cfb716"}, "9591e85f-fd5b-462c-8b35-c4874f654bde": {"doc_hash": "a3076bc9206f5a705dcde88f37dbe6af590984f55f76c896ce1e5d323920babd"}, "89305721-b50d-458c-b539-8f3b5feed0bd": {"doc_hash": "c43c5809f6a0f767c7920f8692ae77f9db0e93afe337208f87331242b0b51980"}, "56bf0e33-4e80-4fac-9b8f-1a418d45563e": {"doc_hash": "37e067768124237b48b00702c96b3abf4a34746686eb21704e891f36059979e5"}, "e52504b3-5057-47b9-a518-b38c93c085d7": {"doc_hash": "61327daa3fcbf3bf355b9e93b33c36b23e7c801559e6bc70fbed64dc63c2abc8"}, "b87b2a23-5be1-465a-8db3-ee1221937513": {"doc_hash": "620726aff35184a0db115a74ae8b59a4d3331cab50b7768994bcb70ce179c774"}, "4b30fa72-0d96-4d4c-8501-338f0fbff9c5": {"doc_hash": "a49d0303fae6e6c378fdcdaead002fc032016cd210582fa5959e0746857649ed"}, "59bba3f0-274c-4ade-8538-fd0e28432ab1": {"doc_hash": "d7775d2e01667bc21b2f47450c79c2d82fb7dce91a8f4e60c907789503967b96"}, "437a834a-0cb4-4c5a-b986-2e608c16e623": {"doc_hash": "30dc777aec08fa2dcf53d4249103035da251b9499b39d645cb66918863219bc2"}, "1d7fa982-ab9a-49cc-ba8b-0896cb97ac4f": {"doc_hash": "f247dbc7892998e58f028c6e81ecc38b68376252aec581fe6ead016e159686b3", "ref_doc_id": "0bfc066a-ba86-40ed-8104-6d4beb6f2d85"}, "f5adf13f-1fa8-4204-8071-95b0da32d2cb": {"doc_hash": "ce62fc0579a0142b8347bbdff219917ebaffb249f24a0735495e6cf1977dcc25", "ref_doc_id": "1107ab99-664b-48a5-b94f-ea9025bf18b8"}, "e54c4926-6c1f-443c-9d9a-a4ae99e52c97": {"doc_hash": "1699ed8bc965be32d2da708d6df6d41bb61dd2de3c172cdb4d8b0423468b03db", "ref_doc_id": "a8717909-0907-4df6-b12a-c03d0343fd63"}, "44b0e9a1-69ef-406b-ae06-ccf611d55b4f": {"doc_hash": "82f150ae706b3f9aaa2ee840b99241d6952ebff528e26579981b3bf6c10d5f87", "ref_doc_id": "cc38eaa8-ce72-49e3-b971-e7dc10b40b27"}, "a5b23d14-b435-462f-903a-34952df58eb9": {"doc_hash": "bbff59910fcd0ce682b81526d1f2fae68bfa384a43e5c5c6cfc5548bfe36883e", "ref_doc_id": "892bb4b6-097f-4f5e-ac43-46cad64c9f8e"}, "d4ce7d22-4984-4c75-a490-d1ca64b21d19": {"doc_hash": "05f47ede26ede51091cf7d17db0a8185b83a533fe910252b1153f6bc90a5d60a", "ref_doc_id": "2b757389-852c-42b7-8b22-598cab104548"}, "f1a11274-4d35-4b79-a6da-9535a1e603a7": {"doc_hash": "838405a229e4d77543693837f83faea33bf79e870d3b71ab67bce7b915f3046f", "ref_doc_id": "f0dcae12-7262-4bd1-b26d-8949e0dd23ff"}, "adbfc440-86ec-4ae7-a37c-ff6ef7c8c5a4": {"doc_hash": "7056df258f3b3ce53f02f067f23f6eb444885086d91d494cf4580e1e497d3679", "ref_doc_id": "4416187a-48b2-4ba2-ba33-967b7851d49c"}, "967333ad-71af-4763-971e-b9fecbed34db": {"doc_hash": "d94f81f587a47a99e5555388bc66741b8f047b4845634f797ffd1c489c70f1d0", "ref_doc_id": "a7311867-ad05-4682-86c6-aa0979a2a0fd"}, "2fa43eaf-a5c2-41b0-8cc3-212e3c63b027": {"doc_hash": "147e871864f2ea9976483087ced2b3fadad61bd5042745b2c7203aeadf1c8adb", "ref_doc_id": "103eab7d-0c6d-4ac8-86dc-b6efcbc69614"}, "01dda873-d2f0-4d4f-9b40-097ec6ef9a4a": {"doc_hash": "e9ed160ea3d8ec3c82358f935bb55a24a58689a76c936e3576581e4c160b243c", "ref_doc_id": "5133dbb4-b887-4acd-a401-e7625d9a4773"}, "070f60c4-5bff-4f3c-91ff-9d0df379d2c2": {"doc_hash": "776fa1138df174a8babe4b96e0c3a7ac026509863b51b7bb12657a41c54e5dc3", "ref_doc_id": "e9add9a4-05a6-40de-8b34-253eabc8f98e"}, "62385a64-e0d9-4506-80c4-3ff712ef0f31": {"doc_hash": "0892236c64864952b8cec1dd6f9ad788d46964c2bec80ff9fbc884db0c63a08d", "ref_doc_id": "b2f4a49f-f2bc-4159-9ed4-1ce70bf7a418"}, "8a074b39-5841-4264-8f48-1be7c0c91348": {"doc_hash": "4ac350b9991b83a735a160d6fdcb46868c1a04b7f498d14ee77f7f03ee98dad8", "ref_doc_id": "da442196-2381-49b8-90ce-0d40bfe337bf"}, "e1ce8045-808b-4cf6-9254-c5a3e1e5176a": {"doc_hash": "2c2452a8fd52ea4d8cf909d6a089942a43ed464fe67946e94bf15315ada5b022", "ref_doc_id": "a116771d-514d-4b60-8024-d3503a4638ae"}, "46332af2-7ced-4675-9b08-b230b898202e": {"doc_hash": "256455968750ede6b62961db700a08dce7ab0e08a27e533b8792c3063e7938a7", "ref_doc_id": "75ec51b9-be27-434e-b6df-d9f261ca2253"}, "4e0610a2-607a-43d7-84c8-c7a1afd961ac": {"doc_hash": "fd66955fabadfb4c51e478e13478112363b10410d280148d74fca9f0cade9825", "ref_doc_id": "076164f0-a19f-4bde-9daa-2d063ab87c93"}, "bbcde0a7-6aac-4fca-bee5-f240a7847d5e": {"doc_hash": "241036e9267ff9a2b2e4c8df7be3a36f32c6f9435fccba1ae6fad0d52271ba11", "ref_doc_id": "ed305f47-a111-4fe0-a483-79212d988b65"}, "c663f792-051a-418d-9568-d1c427515f74": {"doc_hash": "0b6420f2d1bc60071903dcb8d414e0a12dc38ad8b4f1dc2953bba62b8ed1cac6", "ref_doc_id": "9d035547-2b01-4fd6-936a-7a1f11fbb0c5"}, "c4dbfff4-40a6-4636-a304-3653b5b3a892": {"doc_hash": "251f17668d888af167eb1f5711f67cad34eee8b31ef8a2bb59aaa9cebfb166ca", "ref_doc_id": "c908c086-bda0-45ae-b975-e2a4e5192787"}, "b98b919b-f0b5-46fc-92ee-b58412bdb893": {"doc_hash": "cd51675b88d9f0b0ec579c7e3da829b9b4099ce1742bebd5642a410865ab4af0", "ref_doc_id": "a9dbf832-4334-4668-ab56-7c9c889a92c0"}, "6aefacea-a52e-4e93-a138-815c45a2aac9": {"doc_hash": "f210b1ce603b96b677f8c62b45c9511f28277c37b8e68aa1905b09c0488307b5", "ref_doc_id": "2de40199-8596-47f5-8203-98e24286a7c7"}, "3b1d6d1b-6f1e-4b10-b9ae-5d8d20868c39": {"doc_hash": "20c88c30def380f04a9de6b4592f8e337bd960b20f9b12424c5e9fff611e03ab", "ref_doc_id": "595d2b25-1048-4cda-8533-b59b1768ec7c"}, "c3b3edaa-8624-4d94-bd78-628d5f5e3443": {"doc_hash": "08cf22ceed57e5b4232e70cbb77450db208d3054a966bff8222c85deade07916", "ref_doc_id": "2abe2a1d-9183-4862-864a-f2fc074aed8d"}, "3593cd51-54ef-4a72-9632-0183a9c3a728": {"doc_hash": "54e191a1a4ebcfe88cb1d2f967a96c147ec4a86ae412e1bbdfd6c98e04730046", "ref_doc_id": "f0d1f3f5-6bbf-43bb-a474-bbc09a4335bf"}, "3d00c419-4793-4f26-90f3-d1c6904a0287": {"doc_hash": "2cc5b8250af15fa4e14e97cce6dbd92a36f58948b6b28082a4250016635ec616", "ref_doc_id": "9764b622-a0f5-455f-86b2-448bccb6f9c8"}, "fa4c8e04-9869-4cfa-8f8c-69c4f2491505": {"doc_hash": "ef923783c7d8d628f855a1bcf9a99ffabd394ca18d99164877ee08cec25553d8", "ref_doc_id": "07168dc4-6b65-4ea3-bcba-263687653332"}, "8673c0e3-8c3c-44fd-bc35-4d1179863d4c": {"doc_hash": "6fcd585f0a048bf8987e865663f497a051878685a8a1e95b2dea874c6056f7f1", "ref_doc_id": "5adf154b-4e1e-40c6-9f46-002e60ddc559"}, "a23d123d-75c1-4a8e-b33c-d5398a638145": {"doc_hash": "0ead5cdefef74af61418615f307a698042d40b1ac18c373c37d520ce3e439cc1", "ref_doc_id": "14061b51-3fd6-463c-9b1d-53a4e0bf6fb4"}, "e085de5d-e30a-4739-ade6-6bb8d0f177e4": {"doc_hash": "15e5caf228e333e101ec69d77716d69fd63d8cb6c7beffbc3773711491385ff6", "ref_doc_id": "14061b51-3fd6-463c-9b1d-53a4e0bf6fb4"}, "5d542be2-6f5d-448b-82a6-e3e10732d220": {"doc_hash": "760cfa15039a782e30b0aa7f5b0415c29e6c7df4779237808054ec2bebba35e4", "ref_doc_id": "eaa8a52f-a714-4d3e-a134-1c2cc2e39422"}, "fff735ed-980d-4e5e-99ef-af941774cdd2": {"doc_hash": "33fbac1440395984bbbd5a9e9b6267cbbe1f1b94f60849c9071547cec52b1be4", "ref_doc_id": "eaa8a52f-a714-4d3e-a134-1c2cc2e39422"}, "13a862ea-68ca-4d49-8bd2-cdc6ef44f8b7": {"doc_hash": "20531f9a6803a9fb4262796745b2b8789ecf7d415c8d23c75c56bd395a2c70b3", "ref_doc_id": "7b80ed4a-affa-4944-9bea-8d3cba483d10"}, "fd01ca2e-63ac-4ad3-bd77-8b252be795be": {"doc_hash": "92ed1f32ea91e7a7a02e897abaf25e2a1416d59e9259d1fd1ad07b211b23f9bd", "ref_doc_id": "7b80ed4a-affa-4944-9bea-8d3cba483d10"}, "5bf2922c-9507-4f0d-a216-3fdd02f1b18b": {"doc_hash": "a2125a73920be97ea990357e87c5b1a4e67ab902b7ba3dfdc15f001997de38ec", "ref_doc_id": "9591e85f-fd5b-462c-8b35-c4874f654bde"}, "d627cb46-b3e3-4775-972d-33c028defa61": {"doc_hash": "5a64d1106f574c81ac92934d9a1859dfd384d0d491192b6a898bb168216cb27a", "ref_doc_id": "9591e85f-fd5b-462c-8b35-c4874f654bde"}, "be28483e-f94b-4a92-8061-d2d85e44b838": {"doc_hash": "cda23a00008d695c49e8174ea9097edb1c110195ecb6f22d62d69aa519f89497", "ref_doc_id": "89305721-b50d-458c-b539-8f3b5feed0bd"}, "82d8c799-fac4-4de5-bb8d-b19d86b6805a": {"doc_hash": "82ce29d6c168af1a6ae4f393d425dc9ebf5824f45ce54a9d06a362e50f55c86b", "ref_doc_id": "89305721-b50d-458c-b539-8f3b5feed0bd"}, "bd1039e8-478d-4bec-a205-27df6fe0de3d": {"doc_hash": "446e5d41adb6e9fb1192fc7acb92f1aa61ed0c4755cb148075660731f7de3b31", "ref_doc_id": "56bf0e33-4e80-4fac-9b8f-1a418d45563e"}, "dbbd5846-5753-4572-942e-3b31727de57d": {"doc_hash": "8893f89fcd226acfecfab986a7cf97ce33fd6479a97983b7287bada0f6f2d24f", "ref_doc_id": "56bf0e33-4e80-4fac-9b8f-1a418d45563e"}, "36ad5525-4bea-4787-8b4b-7e48b21d4159": {"doc_hash": "90675aafa237f8863c297c3cdb9148409c891d49436bad470a87850258db167d", "ref_doc_id": "e52504b3-5057-47b9-a518-b38c93c085d7"}, "07b742ad-2db3-4264-adeb-eedee52dcd91": {"doc_hash": "1304bf6ea9cee4b97f9ac33ffb2baa50522fb0309222e18558eb2b832e4a150a", "ref_doc_id": "e52504b3-5057-47b9-a518-b38c93c085d7"}, "67f8569b-d127-4360-81bc-6456452f0cf9": {"doc_hash": "fe35783be6d9c4883d6c1eaf8f63b9e88ba12cf6ebe7d13138b037a4cffd89d8", "ref_doc_id": "b87b2a23-5be1-465a-8db3-ee1221937513"}, "8ddf7af6-435b-4257-9022-8363dfe93cd2": {"doc_hash": "d4a01bc81dc08470987d382780d91c95c97d2887dca08f6e3285cb9feac511db", "ref_doc_id": "b87b2a23-5be1-465a-8db3-ee1221937513"}, "c5c03a8b-8f7a-4b65-918a-3716365e8529": {"doc_hash": "8f150babb113f971f0427991ff9c28116a3fd7adfa659cc8329cd824b2fc7cbf", "ref_doc_id": "4b30fa72-0d96-4d4c-8501-338f0fbff9c5"}, "5c4fa3c0-3c38-4ff1-9d1d-f37950055f36": {"doc_hash": "bed8f085d2a4a825b5c1c97c3efe205537198c6c8e5fd6c579294421c5f2cc5e", "ref_doc_id": "4b30fa72-0d96-4d4c-8501-338f0fbff9c5"}, "4225d9ac-4cad-4a20-8a7e-21531a6d6063": {"doc_hash": "56cb22d14e37358edab96f933f49bb99b441a4bfa35d22305edafa9410eb68b5", "ref_doc_id": "59bba3f0-274c-4ade-8538-fd0e28432ab1"}, "bec8d9b0-9048-4088-ba4f-b043fd710713": {"doc_hash": "393afa95ed9ff4a877b2627e9d93a11e6c38774cf870201ff4c5b843af540750", "ref_doc_id": "59bba3f0-274c-4ade-8538-fd0e28432ab1"}, "68983b9b-6c16-4a4d-a5a2-8d4ee617a21a": {"doc_hash": "75238b51973fda49cd8471f7d7ae9d3b12783aa4848cb3c9beeb7f4b1b5cd9ec", "ref_doc_id": "437a834a-0cb4-4c5a-b986-2e608c16e623"}}, "docstore/data": {"1d7fa982-ab9a-49cc-ba8b-0896cb97ac4f": {"__data__": {"id_": "1d7fa982-ab9a-49cc-ba8b-0896cb97ac4f", "embedding": null, "metadata": {"file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\notes.txt", "file_name": "notes.txt", "file_type": "text/plain", "file_size": 8, "creation_date": "2024-05-17", "last_modified_date": "2024-05-15"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0bfc066a-ba86-40ed-8104-6d4beb6f2d85", "node_type": "4", "metadata": {"file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\notes.txt", "file_name": "notes.txt", "file_type": "text/plain", "file_size": 8, "creation_date": "2024-05-17", "last_modified_date": "2024-05-15"}, "hash": "a13aa66291e3d87b4fec54be664d2dc79aeed74114559331571d71f932f807f8", "class_name": "RelatedNodeInfo"}}, "text": "Haseeb", "start_char_idx": 0, "end_char_idx": 6, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5adf13f-1fa8-4204-8071-95b0da32d2cb": {"__data__": {"id_": "f5adf13f-1fa8-4204-8071-95b0da32d2cb", "embedding": null, "metadata": {"page_label": "1", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1107ab99-664b-48a5-b94f-ea9025bf18b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "ce62fc0579a0142b8347bbdff219917ebaffb249f24a0735495e6cf1977dcc25", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients  2013 , 5, 3646-3683; doi:10.3390/nu5093646 \n \nnutrients \nISSN 2072-6643 \nwww.mdpi.com/journal/nutrients \nReview \nNutritional Recommendations for Cardiovascular  \nDisease Prevention \nSigal Eilat-Adar 1,*, Tali Sinai 2, Chaim Yosefy 3,4 and Yaakov Henkin 4,5 \n1 Zinman College for Physical Education & Sports, Wingate Institute, Netanya 42902, Israel \n2 School of Nutritional Sciences, In stitute of Biochemistry, Food Scie nce and Nutrition, The Robert H. \nSmith Faculty of Agriculture, Food and Environmen t, The Hebrew University of Jerusalem,  \nRehovot 76100, Israel; E-Mail: Tali.sinai@mail.huji.ac.il \n3 Cardiology Department, Barzilai Medical  Center Campus, Ashkelon 78000, Israel;  \nE-Mail: yosefy@ba rzi.health.gov.il \n4 Ben-Gurion University of the Negev, Beer  Sheva 84105, Israel; E-Mail: yaakovh@bgu.ac.il \n5 Cardiology Department, Soroka University  Medical Center, B eer-Sheva 84101, Israel \n* Author to whom correspondence should be a ddressed; E-Mail: siga leilat70@gmail.com;  \nTel.: +972-54-440-0029; Fax: +972-3-648-6451. \nReceived: 11 July 2013; in revised form: 26 August 2013 / Accepted: 27 August 2013 /  \nPublished: 17 September 2013  \nAbstract:  Lifestyle factors, including  nutrition, play an important role in the etiology of \nCardiovascular Disease (CVD). This position paper, written by collaboration between the \nIsrael Heart Association and the Israel Di etetic Association, su mmarizes the current, \npreferably latest, literature on the associa tion of nutrition and CVD with emphasis on the \nlevel of evidence and practical recommendations . The nutritional information is divided into \nthree main sections: dietary patterns, indivi dual food items, and nutritional supplements. The \ndietary  patterns reviewed include low carbohydrate di et, low-fat diet, Mediterranean diet, \nand the DASH diet. Foods reviewed in the seco nd section include: whol e grains and dietary \nfiber, vegetables and fruits, nuts, soy, dairy products, alcoholic drinks, coffee and caffeine, \ntea, chocolate, garlic, and eggs. Supplements reviewed in the third section include salt  \nand sodium, omega-3 and fish oil, phytostero ls, antioxidants, vitamin D, magnesium, \nhomocysteine-reducing agents, and coenzyme Q10.  \nKeywords:  guidelines; nutrition; ca rdiovascular; prevention  \n OPEN ACCESS", "start_char_idx": 0, "end_char_idx": 2316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e54c4926-6c1f-443c-9d9a-a4ae99e52c97": {"__data__": {"id_": "e54c4926-6c1f-443c-9d9a-a4ae99e52c97", "embedding": null, "metadata": {"page_label": "2", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a8717909-0907-4df6-b12a-c03d0343fd63", "node_type": "4", "metadata": {"page_label": "2", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "efbc8660ff18057cd186140e798376898e7d18c573dc3f729c905727af7498f4", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3647 \n \n1. Introduction \nLifestyle factors, includ ing nutrition, play an important role in the etiology of Cardiovascular  \nDisease (CVD). This position paper is written by coll aboration of the Israel Heart Association and the \nIsrael Dietetic Association. \nWe conducted a comprehensive literature search through electronic databases up to December 2012. \nWe systematically searched published meta-analysis of intervention or cohort prospective studies that \ninvestigated the association betw een the relevant keywords of th e chapter topic and cardiovascular \nhealth outcomes in electronic databases: The Cochra ne Library (source: The Co chrane Central Register \nof Controlled Trials, Pubmed and Google Scholar . When multiple articles for a single study were \npresent, we used the latest publicat ion the most complete one. If need ed, general historical information \nwas added. \n\u201cIf there were not enough data on cardiovascular morbidity or mort ality (\u2018hard CV end points\u2019),  \nwe searched for a possible influence on dyslipidemia or CVD risk factors (suc h as in the DASH diet)\u201d. \nAs nutritional data has limited \u201chard endpoint\u201d data, especially from randomized trials, we needed to \ncategorize some of the data base d on surrogate e ndpoints as well. \nThe data were summarized literature with emphasi s on the level of evidence (Table 1) and practical \nrecommendations (Table 2) [1]. \nTable 1.  Levels of evidence. \nA Data derived from multiple randomized clinical trials or meta-analyses \nB Data derived from a single randomized clinical trial or large non-randomized studies \nC Consensus of opinion of the experts and/or small studies, retrospective studies, registries \nTable 2.  Strength of statement and/or recommendation.  \nClass of recommendation Defini tion Suggested wording to use\nClass I Evidence and/or general agreement that a given statement and/or \nrecommendation is beneficial It is recommended/is \nindicated \nClass II Conflicting evidence and/or a divergence of opinion about the \nusefulness/efficacy of the statement and/or recommendation  \nClass IIa Weight of evidence/opinion is in favor  of usefulness/efficacy Should be considered \nClass IIb Usefulness/efficacy is less well estab lished by evidence/opinion May be considered \nClass III Evidence or general agreement that the treatment is not useful/effective \nand, in some cases, may be harmful It is not recommended \nOnce the document has been finalized and approved by all the experts involved in the committee,  \nit was submitted to outside specialists from the Isra eli Heart Society and Israel i Dietetic Association  \nfor review. \nThe nutritional information is divided into three main sections: dietary pa tterns, individual food \nitems, and nutritional su pplements. The dietary  patterns reviewed include low carbohydrate diet, low-fat \ndiet, Mediterranean diet, and the DAS H diet. Foods reviewed in the seco nd section include: whole grains \nand dietary fiber, vegetabl es and fruits, nuts, soy, dairy products,  alcoholic drinks, coffee and caffeine, \ntea, chocolate, garlic, and eggs. Supplements revi ewed in the third secti on include salt and sodium,", "start_char_idx": 0, "end_char_idx": 3166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44b0e9a1-69ef-406b-ae06-ccf611d55b4f": {"__data__": {"id_": "44b0e9a1-69ef-406b-ae06-ccf611d55b4f", "embedding": null, "metadata": {"page_label": "3", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cc38eaa8-ce72-49e3-b971-e7dc10b40b27", "node_type": "4", "metadata": {"page_label": "3", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "f4659fe3b19f0fa75b1e555f8d93829ff4265e63fee849e183c3a4c8e914e4df", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3648 \n \nomega-3 and fish oil, phytosterols, antioxidants, vitamin D, magnesium, homocysteine-reducing agents, \nand coenzyme Q10. \n2. Dietary Patterns \n2.1. Low-Fat Diets \nThe consumption of a lower fat diet is generally accepted in all clinical guidelines on CV prevention, \nand will therefore not be discussed in detail in this manuscript. Brie fly, the diet is based on total fat \nconsumption of 25%\u201335% of total calories, of wh ich, saturated fat (SFA) should be no more than \n7%\u201310%, trans fat (TFA) less  than 1%, unsaturated fats, mainly monounsatur ated fats (MUFA) and \nomega-3 polyunsaturated fat ( n-3 PUFA) should represent the rest of the calories from fat and \ncholesterol, for a total of less than 300 mg/day [2 ]. These recommendations can be achieved by choosing \nlow-fat meats and emphasizing vegetables, low-fat dairy products and 1% milk, and lowering food \ncontaining TFA [3]. Genera lly, this diet increases the carbohydr ate intake, and controversy remains \nabout the type and amount of carbohydrate consumed [4].  \n2.2. Low-Carbohydrate Diets \nA low-carbohydrate diet is define d as consumption of 30\u2013130 g of carbohydrate per day or up to 45% \nof total calories [5]. Intervention studies resulted in  a reduction in triglycerides (TG) and increase in \nHDL-cholesterol (HDL-C) [6]. The most recent sy stematic [7] review and meta-analysis among  \n1141 obese patients, showed the low-carbohydrate diets to  be associated with significant decreases in \nbody weight ( \u22127.04 kg (95% CI \u22127.20/\u22126.88)), body mass index (BMI) ( \u22122.09 kg/m2) (95% CI \n\u22122.15/\u22122.04), systolic blood pressure ( \u22124.81 mmHg (95% CI \u22125.33/\u22124.29)), diastolic blood pressure \n(\u22123.10 mmHg (95% CI \u22123.45/\u22122.74)), plasma TG ( \u221229.71 mg/dL (95% CI \u221231.99/\u221227.44)), as well as \nan increase in HDL-C (1.73 mg/dL) [95% CI 1.44/ 2.01]. Low-density lipoprotein cholesterol (LDL-C) \nand creatinine did not change significantly. The aut hors concluded that low-carbohydrate diets result in \nfavorable effects on body weight and major CV risk factors; however, the effects on long- term health are \nunknown. A two-year Dietary Inte rvention Randomized Controlled  (DIRECT) trial among  \n322 moderately obese participants that compared low-fat, Medite rranean, and low- carbohydrate diets \nfound that compared to the other di ets, the low-carbohydrate diet was most effective in weight loss, \ndecreasing TG and increasing HDL-C levels [8]. Howe ver, at follow-up four years after completion of \nthe randomized study, the weight regain in the lo w-carbohydrate group was also most prominent, \nresulting in similar overall weight  loss between the low- fat and low-carbohydrate groups. Despite this \npartial weight regain, there was a reduction in the ratio of LDL-C to HDL-C (a reduction of 0.16,  \np = 0.04), and the reduction in TG levels (11.3 mg/dL, p = 0.02) remained significant in the \nlow-carbohydrate group, suggesting a long-lasting, favorable post-intervention effect.  \n2.3. Mediterranean Diet \nThe Mediterranean diet was origin ally described in Crete and Italy, and is characterized by a \nrelatively high fat intake ( 40%\u201350% of total daily calorie s), of which SFA comprises \u22648% and MUFA \n15%\u201325% of calories. It is characterized by a high omega-3 fatty acid intake from fish and plant", "start_char_idx": 0, "end_char_idx": 3295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5b23d14-b435-462f-903a-34952df58eb9": {"__data__": {"id_": "a5b23d14-b435-462f-903a-34952df58eb9", "embedding": null, "metadata": {"page_label": "4", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "892bb4b6-097f-4f5e-ac43-46cad64c9f8e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "e614cc6fd01d3449ce2a8b5509e84ea522f68eedd13b777918234717531cf303", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3649 \n \nsources and a low Omega-6:Omega-3 ratio of 2:1\u20131:1 co mpared to 14:1 in Europe [9,10]. It is based \non seasonal, local, fresh vegetables, fruits, whol e bread and grains, legumes , nuts, and olive oil. \nModerate intake of dairy products (low-fat), as well as eggs, fish, and chicken are allowed, while red \nmeat is avoided. Small to moderate quantities of wine  are encouraged with meals [8]. Adherence to the \nMediterranean diet was associated with a low risk of coronary he art disease (CHD), as shown in a \nmeta-analysis of seven cohort studies ; a 2-point increase in adherenc e to the Mediterranean diet was \nassociated with a significant reduction of ove rall mortality. RR = 0.92; [95% CI 0.90\u20130.94], CV \nincidence or mortality (RR = 0.90; (95% CI 0.87\u20130.93)) [11]. In a multicen ter random intervention \ntrial in Spain, participants who were at high cardiova scular risk, but with no cardiovascular disease at \nenrollment, were divided to one of  three diets: a Mediterranean diet  supplemented with extra-virgin \nolive oil, a Mediterranean diet supplemented with  mixed nuts, or a contro l diet (advice to reduce \ndietary fat). The primary end point was the rate of major cardiovascular  events (myocardial infarction, \nstroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial \nwas stopped after a median follow-up of 4.8 years. \nThe multivariable-adjusted HR were: HR = 0.70 (95% CI 0.54\u20130.92) and 0.72 (95% CI, 0.54\u20130.96) \nfor the group assigned to a Mediterranean diet w ith extra-virgin olive o il (96 events) and the  \ngroup assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group  \n(109 events). No diet-related adve rse effects were reported. This st udy confirmed that, among persons at \nhigh cardiovascular risk, a Mediterran ean diet supplemented with extra- virgin olive oil or nuts reduced \nthe incidence of major car diovascular events [12]. \n2.4. Dash Diet \nThe Dietary Approach to Stop Hype rtension (DASH) diet is a nutri tional program assembled in the \n1990s and assessed in intervention c ontrolled trials. Its main target was to lower blood pressure, and \ntherefore CVD incidence, by nutritional means. The DAS H diet comprises vegetables and fruits, as well \nas low-fat dairy products, whole grains , chicken, fish, and nuts. On the ot her hand it is low in fat, meat, \nsweets, and sodas. The DASH diet, summarized in Table 3, provides more calcium, potassium, \nmagnesium, and dietary fiber and less fat, SFA, cholesterol, and sodium than the typical western diet [13]. \nTable 3.  Dietary Approach to Stop Hypertensi on (DASH) diet composition [13]. \nNutrient Daily quantity \nTotal fat 27% of total calories \nSFA 6% of total calories \nCarbohydrates 55% of total calories \nProtein 18% of total calories \nCholesterol 150 mg \nFiber 31 g \nPotassium 4700 mg \nMagnesium 500 mg \nCalcium 1240 mg \nRecommendations and level of r ecommendations of dietary pattern s are summarized in Table 4.", "start_char_idx": 0, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ce7d22-4984-4c75-a490-d1ca64b21d19": {"__data__": {"id_": "d4ce7d22-4984-4c75-a490-d1ca64b21d19", "embedding": null, "metadata": {"page_label": "5", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2b757389-852c-42b7-8b22-598cab104548", "node_type": "4", "metadata": {"page_label": "5", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "b4e958ba7d8583e822cc698db14c59e8c7ba16cc7fb7466ed27ceea5f513c0a0", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3650 \n \nTable 4.  Level of evidence and classes of recommendations for food patterns. \nFood pattern  Recommendations Strength Level of \nevidence  \nLow-fat diet  Low-fat diet with restricted calories may present a h ealthy alternative to the typical Western diet. It \nmay improve quality and life expectancy in hea lthy people, as well as in patients with overweight, \ndiabetes, and CVD.  II a A \nLow-carbohydrate Diet In the short-run, low-carbohydrate diets lead to a gr eater weight loss compared to low-fat diets. Some \nstudies have shown that this advantage is retained  at 2 years but not at longer follow-up periods  II b A \nLow-carbohydrate diets are preferable to a low-fat diet in reducing TG levels and increasing HDL-C \nblood levels. It should be emphasized that carbohydrat es should preferably be replaced by unsaturated \nvegetable fats.  II a A \nLow-carbohydrate diets, which include 30%\u201340% of calories from carbohydrates and are low in saturated fat and high in monounsaturated fat, we re found to be safe in healthy and overweight \nindividuals at follow-up up to 4 years.\n II a A \nMediterranean Diet  A Mediterranean diet with restricted calories may present a healthy alternative to the typical Western \ndiet. It may improve quality and life expectancy in healthy people, as well as in patients with \noverweight, diabetes, and CVD.  II a A \n Mediterranean diets are preferable to a low-fat di et in reducing TG levels, increasing HDL-C blood \nlevels, and improving insulin sensitivity.  II a A \nDASH Diet  The DASH diet is recommended to prevent hypertension and lower blood pressure.  I A \nThe diet should be accompanied by lifestyle chang es such as: weight reduction in overweight people, \nincreased physical activity, sodium restriction, and alcohol avoidance.  I A", "start_char_idx": 0, "end_char_idx": 1806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1a11274-4d35-4b79-a6da-9535a1e603a7": {"__data__": {"id_": "f1a11274-4d35-4b79-a6da-9535a1e603a7", "embedding": null, "metadata": {"page_label": "6", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f0dcae12-7262-4bd1-b26d-8949e0dd23ff", "node_type": "4", "metadata": {"page_label": "6", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "18a907982bb59f068bc29476e7ca9a5d9c8460e6c2d6bb7d3a63b9e2eef6ff15", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3651 \n \nCompared to the typical western di et, the DASH diet reduced  systolic and diastolic  blood pressure by \n11.4 and 5.5 mmHg, respectively, and by 7.2 and 2.8 mmHg, re spectively, in patien ts with hypertension \n(HTN). The blood pressure decrease was observed in normotensive partic ipants as well [14,15]. Adding \nsodium restriction to the DASH diet further reduced th e blood pressure [16]. It  also improved autonomic \nand vascular function and lowered left ventricula r mass among overweight patients with HTN. This \ninfluence was most prominent when accompanied by weight reduction and increased physical  \nactivity [17]. The PREMIER trial combined the DASH diet with a lifestyle pr ogram aimed at reducing \noverweight, increasing physical activit y, and restricting sodium and alcohol intake. In patients with \nHTN, systolic and diastolic blood pressures were reduced by 14.2 and 7.4 mmHg, respectively.  \nA decrease in blood pressure was observed in normot ensive participants as well [15]. Based on these \ndata, the theoretical decrease in Framingham risk sc ore for CHD was 12% greater  when adding lifestyle \nchanges to the DASH diet [18]. \n2.5. Conclusions \nAll four dietary patterns described above are usef ul for reducing CVD risk factors, and some have \nalso shown a favorable effect on plaque regression [19] and CVD mortality [16]. Thus, every patient \nshould adopt a dietary approach that conforms to hi s or her personal preferen ces; however, the long-term \neffects of some of these diets, and especially a high saturated-fa t, low-carbohydrate diet, on CVD and \ntotal mortality have not been fully assessed. \n3. Individual Food Items \n3.1. Whole Grains and Dietary Fiber \nWhole grains represent unprocessed grains that contain the endosperm ; the bran (the outer layer of \nthe whole grain) and the germ are in the same relative  proportions as they exist in the intact grain. In \ncontrast, refined grains retain only the endosperm. Common whole gr ains include: whole wheat, whole \nrice, barley, corn, rye, oats, millet, sorghum, teff, tritical e, canary seed, J ob\u2019s tears, fonio, and wild rice [20]. \nDietary fiber consists of the remnants of edible  plant cell polysaccharides, lignin, and associated \nsubstances resistant to hydrolytic digestion by the human alimentary enzymes [21]. They can be divided \ninto: insoluble fiber, which includ es cellulose and lignin, and is found in vegetabl es, some fruits, and \nwhole grains (including the wheat germ); and soluble fiber, which in cludes fruits, pectin, guar gum, and \nmucilage. Soluble fiber is found in legumes and in oa t bran [22]. In a Cochrane  review, 10 studies of  \n4\u20138 weeks duration that included 56\u201385 g of fiber in individuals with CHD or CHD risk factors were \nreviewed. Eating whole grains de creases total cholesterol levels  by 7.7 mg/dL (95% CI 3.9\u201312) and \nLDL-C levels by 6.9 mg/dL (95% CI 3.5\u201310.8) [23]. In  a meta-analysis of 67 controlled intervention \ntrials, daily consumption of 2\u201310 g/day soluble fiber (mainly beta-glucan, psyllium, and pectin) lowered \nLDL-C by 2.2 mg/dL (95% CI  1.7\u20132.7) with no si gnificant changes in HDL-C or  triglycerides (TG) [24].  \nThe American Heart Association (AHA) [3], The American Dietetic Association [25] and the \nNational Cholesterol Education Program (ATP III) [26] guidelines include a recommendation to \nincrease dietary soluble fiber inta ke. The question of whether added fi ber used as a food supplement can \nsimilarly protect against CVD is still controversia l. Despite this, the Food and Drug Administration", "start_char_idx": 0, "end_char_idx": 3583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adbfc440-86ec-4ae7-a37c-ff6ef7c8c5a4": {"__data__": {"id_": "adbfc440-86ec-4ae7-a37c-ff6ef7c8c5a4", "embedding": null, "metadata": {"page_label": "7", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4416187a-48b2-4ba2-ba33-967b7851d49c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "e16f48c20e0b3f9c44ceb73ee825173ed7ffa76df7adf2b9586bc02ae3c25cf0", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3652 \n \n(FDA) approved a health claim on soluble fiber fr om whole oats, whole grain barley products, and \nbarley beta fiber [27]. The DRI recommends consump tion of 14 g dietary fiber per 1000 kcal, or 25 g for \nadult women and 38 g for adult men [22].  \n3.2. Vegetables and Fruits \nAlthough the botanic term \u201cfruit\u201d refe rs to the seeds and su rrounding tissues of a pl ant, the foods that \nare commonly referred to as \u201cfruits\u201d for culinary pur poses are pulpy seeded tissues that have a sweet \n(oranges, apples, pears, blueberrie s) or tart (lemons, limes, cranberri es) taste. By culinary definition, \n\u201cvegetables\u201d are edible plant parts including stems and stalks (celery), roots (car rots), tubers (potatoes), \nbulbs (onions), leaves (spinach, lettuce), flower s (artichokes), some fruits (cucumbers, pumpkin, \ntomatoes), and seeds (beans, peas). Vegetables are in general less sweet or tart than fruits [28]. \nThe evidence that vegetables and fruits are asso ciated with reduced CHD risk is based only on \nepidemiological data. In a meta-analysis of ni ne cohort studies (inclu ding 91,379 men, 129,701 women, \nand 5007 CHD events), CHD risk was lower by 7%  for each additional fruit serving a day (RR 0.93, \n95% CI 0.89\u20130.96; p < 0.001) [29]. The association between vegetable intake and CHD risk was \nheterogeneous and more marked fo r CV mortality (0.74, 95% CI 0.75\u20130.84; p < 0.0001) than for fatal \nand nonfatal myocardial in farction (0.95, 95% CI 0.92\u20130.99; p < 0.006). \nThere are no interventional studies that specifically evaluated the in fluence of vegetables and fruits \non CHD risk. In interventional studies  where vegetable and fruit consum ption was part of the nutritional \nrecommendations, CHD risk reduction was documente d [10,11]. Vegetable and fruit consumption was \nassociated with lower blood pressure [13\u201315,18], but the association with other C HD risk factors is not \nclear. Despite the lack of intervention studies, the American Heart Association (AHA) recommends \nintake of at least 8 vegeta bles and fruits a day [3]. \nThe mechanism of action is not kno wn, but it is assumed that the h ealthy effect of vegetables and \nfruits can be attributed to the dietary fiber and antioxidants in th ese food items [30]. Vegetables and \nfruits also act as a low-calori e, low-sodium, and satiating food. \n3.3. Nuts \nNuts (tree nuts and peanuts) are nutrient-dense foods with complex ma trices rich in unsaturated fatty \nacids and other bioactive compounds: high-quality ve getable protein, fiber, minerals, tocopherols, \nphytosterols, and phenolic compounds [31]. By definition, tree nuts are dry fruits with one seed in which \nthe ovary wall becomes hard at maturity. This group includes almonds, hazelnut s, walnuts, pistachios, \npine nuts, cashews, pecans, macadamias, and Br azil nuts. The consumer definition also includes \npeanuts, which botanically are groundnuts or legumes but are widely identified as part of the nuts food \ngroup. In addition, peanuts have a nutrient profile simila r to that of tree nuts. Although chestnuts are tree \nnuts as well, they are different from all other common nuts because of being starchier and having a \ndifferent nutrien t profile [32\u201334]. \nEpidemiological data show a consistent negativ e association between nuts consumption and CHD \nrisk [34]. Some of the studies found a dose-response pa ttern of association. An an alysis of four studies \nfrom the United States concluded that  high nut intake is associated with  a 35% risk reduct ion for CVD [35].", "start_char_idx": 0, "end_char_idx": 3544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "967333ad-71af-4763-971e-b9fecbed34db": {"__data__": {"id_": "967333ad-71af-4763-971e-b9fecbed34db", "embedding": null, "metadata": {"page_label": "8", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a7311867-ad05-4682-86c6-aa0979a2a0fd", "node_type": "4", "metadata": {"page_label": "8", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "6490ca8fedaaa6dd71119c2d5b924af12a2506bd14bd344e85dfb762fe0feb5c", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3653 \n \nA pooled analysis was done using data from 25 in tervention nut consumption trials (including \nwalnuts, almonds, macadamias, pecans, peanuts, a nd pistachios) conducted in seven countries among \n583 men and women with normolipidemia and hypercholesterolemia who were not taking \nlipid-lowering medications. With a mean daily consumption of 67 g of nuts, LDL-C concentration was \nreduced by a mean of 10.2 mg/dL ( \u221213.1 to \u22127.4 mg/dL, 7.4% reduction, p < 0.01), with no significant \nchange in HDL-C levels. Mean TG levels were reduced by 20.6 mg/dL ( \u221230.7 to \u22129.9 mg/dL, 10.2% \nreduction, p > 0.05) in subject s with blood trig lyceride levels \u2265150 mg/dL but not in those with normal \nTG levels. The effects of nut consumption were dose  related. Different types of  nuts had similar effects \non blood lipid levels. The lipid-lowering effects were  greatest among subjects with  high baseline LDL-C \nand with low BMI [36]. However, there are no tr ials relating consump tion to CVD endpoints. \nPossible Mechanisms \nThe mechanism of action can be at tributed to the high polyunsaturat ed fatty acids (PUFA) and low \nSFA content. Some nuts (such as walnuts) also c ontain alpha-linolenic fatt y acid. Other macronutrients \ninclude plant protein and fiber; micr onutrients including po tassium, calcium, magne sium, and tocopherols; \nand phytochemicals such as phytoste rols, phenolic compounds, resverat rol, and arginine [35]. Those \nnutrients may have a beneficial eff ect on blood lipids as well  as other CHD risk f actors such as oxidation \nand inflammation. It is also possible that the s ubstitution of high SFA, sodium, and sugar food by nuts \nand almonds can also explain this positive effect. \n3.4. Soy \nSoy protein refers to the protein that is found in soybeans and is often used to repl ace animal protein \nin an individual\u2019s diet. The soybean is a legume that contains no cholesterol and is low in saturated fat, \nand is the only vegetable food that contains all eight essential amino acids. Soybeans are also a good \nsource of fiber, iron, calcium, zinc, and B vitamins [37]. Soy beans are the be st known and most widely \nconsumed food that contains phytoe strogen (isoflavones), which are  plant  components that interact with \nmammalian endocrine systems [38]. \nIntervention Studies \nIn 22 randomized trials, isolated soy protein with isoflavones was compared with casein or milk \nprotein, wheat protein, or mixed anim al proteins. The range of soy prot ein was 25 to 135 g/day; the range \nfor isoflavones was 40 to 318 mg/day. LDL or non-HDL cholesterol concentrati ons decreased in most \nstudies, statistically significantly in 8, with an overall effect of about 3% (weighted average). In a \nmeta-analysis soy protein isolate, but not other soy products or components, significantly reduced \ndiastolic blood pressure (9 studi es, mean reduction 1.99 mmHg; 95% CI \u22122.86, \u22121.12) and LDL-C  \n(39 studies, mean reduction 7.3 mg/dL; 95% CI \u22129.3, \u22125.4) [39]. \nAlthough the improvement in lipoproteins and blood pr essure induced by soy protein is of small and \nquestionable clinical significance, consumption of soy protein-rich foods may indirectly reduce CVD \nrisk if it replaces animal products that contain saturated fat and cholesterol [3] .", "start_char_idx": 0, "end_char_idx": 3285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fa43eaf-a5c2-41b0-8cc3-212e3c63b027": {"__data__": {"id_": "2fa43eaf-a5c2-41b0-8cc3-212e3c63b027", "embedding": null, "metadata": {"page_label": "9", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "103eab7d-0c6d-4ac8-86dc-b6efcbc69614", "node_type": "4", "metadata": {"page_label": "9", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "232f10c9488a1bd94a8434e5758e0fa84b7f5ef5be4b8b8b9de5e8507c6252ac", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3654 \n \nIn October 1999, the FDA approved labeling for foods  containing soy protein as protective against \ncoronary heart disease. The FDA based this decision on clinical studies showing th at at least 25 g of soy \nprotein per day lowered total and LDL cholesterol. Th e FDA requires for the claim that a serving contain \nat least 6.25 g of soy protein, 25% of the necessary da ily quantity of protein (25 g), with the expectation \nthat foods containing soy protein would be eaten at least four times per day. The FDA also stated that \n\u201cthe evidence did not support a sign ificant role for soy isoflavones in cholesterol-lowering effects of soy \nprotein\u201d [40]. However, caution should be exercised when extrap olating this recommendation to \nprocessed meats, which may include soy components , as a meta-analysis f ound a 42% higher risk of \nCHD ( n = 5 studies; RR per 50 g servi ng per day = 1.42; 95% CI 1.07\u20131.89; p = 0.04) [41] in individuals \nconsuming processed meats.  \nThe hormonal effects of dietary soy and soy extracts  were extensively evalua ted. A meta-analysis of \n178 studies revealed inconsistent effects on climact eric symptoms [40]. A nother meta-analysis of \nprospective studies suggested that so y isoflavone intake is associated with a significant reduced risk of \nbreast cancer incidence in Asian populations, but not in Western popul ations [42], a lthough there was no \ndose-response relationship between total isoflavone intake and risk  of breast cancer incidence. \n3.5. Dairy Products \nDairy products are rich in minerals (calcium, pota ssium, and magnesium), protein (casein and whey), \nand vitamins (riboflavin and vitamin B-12) that can ex ert beneficial effects on CVD. On the other hand, \nthe presence of saturated fat in dairy products causes concern over pot ential adverse CV effects [43].  \nThere is conflicting evidence on the association between dairy intake and CVD. The number of \ncohort studies that give evidence on individual dairy food items is very small. However, a meta-analysis \nsuggests a reduced risk in the subjects with the hi ghest dairy consumption relative to those with the \nlowest intake: RR = 0.87 (95% CI 0.77\u20130.98) for all- cause deaths (6 studies), RR = 0.92 (95% CI \n0.80\u20130.99) for ischemic heart disease (9 studies),  and RR = 0.79 (95% CI 0.68\u20130.91) for stroke  \n(13 studies) [44]. In another meta-a nalysis of 17 prospective studies, a modest inverse association was \nfound between milk intake and ri sk of overall CVD (4 studies); RR = 0.94 per 200 mL/day (95% CI \n0.89\u20130.99). Milk intake was not associated with risk of CHD, stroke, or total mo rtality. When stratified \ninto high-fat and low-fat dair y products no significant associat ions were found with CHD [45]. \n3.5.1. Possible Mechanisms \nSuggested mechanisms for the blood-pressure lowe ring effects of dairy pr oducts include the high \ncontent of potassium, magnesium, and calcium. In the DASH diet, the combination diet rich in fruits, \nvegetables, and 2.7 servings per day of dairy products  (predominantly low-fat), substantially lowered \nblood pressure [16]. An association between calciu m intake and lower body weight and fat mass has \nbeen described [46]. There is some evidence that certain ferm ented products (especially by \nLactobacillus helveticus ) have a mildly decreasing effect on HTN, probably because of bioactive \npeptides [47]. The lack of effect of the high saturated fat content on LDL-C levels is attributed to the \nunique fatty acid composition of dairy products, consis ting mostly of short-chain fatty acids and  \nstearic acid.", "start_char_idx": 0, "end_char_idx": 3603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01dda873-d2f0-4d4f-9b40-097ec6ef9a4a": {"__data__": {"id_": "01dda873-d2f0-4d4f-9b40-097ec6ef9a4a", "embedding": null, "metadata": {"page_label": "10", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5133dbb4-b887-4acd-a401-e7625d9a4773", "node_type": "4", "metadata": {"page_label": "10", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "716f35479b5e29f46b47208dd6a1b6825112816b1cdb5acc0156233c5a2f48fc", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3655 \n \n3.5.2. Conclusions \nDespite the contribution of dairy products to the saturated fatty acid composition of the diet, and \ngiven the diversity of dairy foods of widely differ ing fat composition, there is no clear evidence that \ndairy food consumption is consistently  associated with a higher risk of CVD [48] and some evidence that \nlow-fat products may have bene ficial effects on blood pressure.  \nThe general health recommendation is  to prefer low-fat products in order to reduce SFA intake.  \nThis recommendation is based on data from the Nurs e\u2019s Health Study, in which the high-fat to low-fat \ndairy consumption ratio was associated with significantly greater risk [49].  \n3.6. Alcoholic Drinks \nThe consumption of alcohol (ethanol) is widely a ccepted in many social situations. Most data on the \nassociation between alcohol and CVD come from s hort-term interventional studies on the effects of \nalcohol on risk factors as well as long -term observational mortality studies. \nBased on cohort studies, the evidence suggests a J-  or U-shaped relationship between alcohol \nconsumption and risk of CHD [50]. In a meta-ana lysis of 84 prospective c ohort studies, the pooled \nadjusted RR for moderate alcohol drinkers re lative to non-drinkers was 0.75 (95% CI 0.70\u20130.80) for \nCVD mortality (21 studies), 0.71 (95% CI 0.66\u20130.77) fo r incident CHD (29 studi es), and 0.75 (95% CI \n0.68\u20130.81) for CHD mortality (31 studies) [51]. Moderate intake of alcoho lic beverages (1 to 2 drinks \nper day) is associated with a reduced risk of CHD in healthy populations [52]. Th e findings do not \nimplicate an advantage of one t ype of drink over another [53]. \nAmong CVD patients, binge drinkers, defined as those who consumed 3 or more drinks within 1 to  \n2 h, had double the total and CV mortal ity risk of regular drinkers [ 54]. Episodic heavy alcohol drinking, \nbut not moderate drinking, is reportedly associated with  risk of atrial fibrillati on [55]. A detrimental risk \nfor heart disease is not reached when the aver age consumption is 20\u201372 g/day [56]. Excessive \nconsumption is associated with a higher risk for alcohol abuse, hypertension, overweight, various \nmalignancies, automobile accident s, trauma, and suicide [57]. \n3.6.1. Possible Mechanisms \nNumerous mechanisms have been proposed to explai n the benefit of light-to- moderate alcohol intake \non the heart, including an incr ease in HDL-C, reduction in pl asma viscosity and fibrinogen \nconcentration, increase in fibrinol ysis, decrease in platelet aggreg ation, improvement in endothelial \nfunction, reduction in inflammation, and promotion of  antioxidant effects [58,59] . However, despite the \nbiological plausibility and observational data in this regard, these are still insufficient to prove causality. \nDaily intake of more  than moderate amounts of alcoholic bevera ges can also be a risk factor for the \ndevelopment of HTN, increased plasma TG levels, can  serve as a source of ex cess calories, as well as \nincreased risk for breast and other cancers [60]. Patie nts who are hypertensive have high TG levels and \nwomen at high risk of breast cancer should avoid alcoholic  beverages [58].", "start_char_idx": 0, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "070f60c4-5bff-4f3c-91ff-9d0df379d2c2": {"__data__": {"id_": "070f60c4-5bff-4f3c-91ff-9d0df379d2c2", "embedding": null, "metadata": {"page_label": "11", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e9add9a4-05a6-40de-8b34-253eabc8f98e", "node_type": "4", "metadata": {"page_label": "11", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "45f92bf2e4b78bfe43150d25942159d06f896967ea1702a7c9caaec4b6a1edce", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3656 \n \n3.6.2. Conclusions \nDespite the evidence from cohort studies on the inverse association between moderate alcohol \ndrinking and CVD, current guidelines do not reco mmend to begin consuming alcohol for preventing \nCVD. Individuals who regularly c onsume alcohol and who do not have a family history of cancer should \ndo so in moderation\u2014the equivalent of no more than one drink in wome n or two drinks in men per day  \n(Table 5). Alcohol should be avoi ded in pregnant women [54]. Peopl e who intend to drive should avoid \ndrinking alcohol. \nTable 5.  Energy content and ethanol in  alcoholic be verages [61]. \n Spirits  Wine  Beer  \nThe drink portion size (mL) 45 150 350 \nEnergy (kca/portion) 100 120\u2013125 150 \nEthanol (g/portion) 14\u201315 15 14 \n3.7. Coffee and Caffeine \nCoffee is one of the most widely consumed beve rages in the world. The remaining sources of  \ncaffeine include primarily tea, cocoa products, cola beverages, and \u201cenergy\u201d drinks [62]. Caffeine \n(1,3,7-trimethylxanthine) is by far the best charact erized compound in coffee. Coffee also contains \nchlorogenic acid, flavonoids, melanoidins, and vari ous lipid-soluble compound s such as furans,  \npyrroles, anmaltol. Ma ny of these compounds are effi ciently absorbed, have relati vely high bi oavailability, \nand have been shown to have antioxidant propertie s. An estimated 80%\u201390% of adults report regular \nconsumption of caffeine-containing beverages and foods, making it the most widely consumed stimulant \nin the world . There is a possible bias in comparing c affeinated and decaffeinate d coffee. However, most \nepidemiologic studies do not disti nguish former users of caffeinated  coffee who may have switched to \ndecaffeinated coffee because of a health problem, a nd never-users who may be avoiding caffeine as part \nof a healthy lifestyle [63]. Energy content and ethanol in alcoholic beverages  are summarized in Table 6. \nTable 6.  Caffeine content in selected food and drink products.  \nProduct Quantity Caffeine content (mg) \nCoffee, instant 1 glass, 190 mL 75 \nRoasted, ground, perculated or filter, or espresso 1 glass, 190 mL 100\u2013180 \nCoffee, decaffeinated 1 glass, 190 mL 4 \nTea, green 1 glass, 190 mL 24 \nTea, black 1 glass, 190 mL 15\u201324 \nTea, leaf or bag 1 glass, 190 mL 40\u2013100 \nCocoa drink 1 glass, 200 mL 1.1\u20138.2 \nEnergy drinks containing caffeine or Guarana 1 can, 250 mL 28\u201387 \nCoca Cola (regular, diet) 1 can, 330 mL 42 (10\u201370) \nChocolate 50 g 6\u201340 \nBased on date from: Israeli Health Ministry position paper and from [61].", "start_char_idx": 0, "end_char_idx": 2545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62385a64-e0d9-4506-80c4-3ff712ef0f31": {"__data__": {"id_": "62385a64-e0d9-4506-80c4-3ff712ef0f31", "embedding": null, "metadata": {"page_label": "12", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2f4a49f-f2bc-4159-9ed4-1ce70bf7a418", "node_type": "4", "metadata": {"page_label": "12", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "80efad3847b8345d8ce0b6230dec0ae2907270cae52df14295c8e8239022ec50", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3657 \n \nCoffee consumption has long been suspected of bei ng a contributing factor in the development of \nCVD, based mainly on case-control studies [63,64] . However, in the last  few years there are \naccumulated data suggesting no harm [65\u201367], and ev en a protective associa tion between moderate \ncoffee drinking and CHD morbidity a nd CVD mortality [68,69]. Lately, th e risk for developing type 2 \ndiabetes was found to be lower in individuals who consumed four or  more cups of coffee per day \ncompared with those who drank le ss than two cups per day [70]. \n3.7.1. Possible Mechanisms \nSeveral mechanisms have been proposed to explai n the harmful as well as protective effects that \ncertain components of coffee may have on the developm ent of CHD. These includ e the effects of coffee \non blood pressure, serum choleste rol and homocysteine levels, oxidation, and inflammation [65]. \n3.7.2. Conclusions \nAlthough regular consumption of mode rate quantities of coffee seems to  be associated with a small \nprotection against CAD, results from randomized clinical trials about its  beneficial eff ects are lacking. \nAt present, for adults consuming moderate amou nts of coffee (3\u20134 cups/day providing 300\u2013400 mg of \ncaffeine), there is little evidence of  health risks and some evidence of  health benefits [66]. However, \nsome groups, including people with HTN, childre n, adolescents, and the elderly, may be more \nvulnerable to the adverse effects of caffeine. In a ddition, currently available evidence suggests that it \nmay be prudent for pregnant women to limit coffee c onsumption to 3 cups/day providing no more than  \n300 mg/day of caffeine [71]. Fatal or  life-threatening caffeine overdoses  generally involve the ingestion \nof caffeine-containing medica tions. Oral doses of 5\u201350 g (mean 10 g) ha ve resulted in fatalities in adults, \nand the lethal dose is estimated at 100\u2013200 mg/kg of  body weight. Ingestion of  15\u201330 mg/kg has resulted \nin significant toxicity. Sympto ms of caffeine overdose may incl ude agitation, delirium, seizures, \ndyspnea, cardiac arrhythmia, myoclonus, nausea,  vomiting, hyperglycemia, and hypokalemia [72]. \n3.8. Tea \nTea has been one of the most popular bevera ges for 4000 years. Brewed from the plant  \nCamellia sinensis , tea is consumed in different  parts of the world as green, black, or Oolong tea. Of the \ntea produced worldwide, 78% is black tea, which is usually consumed in the Western countries; 20% is \ngreen tea, which is comm only consumed in Asian countries (m ainly Japan and Ch ina); and 2% is \nOolong tea, which is produced (by partial fermentation) mainly in southern China . Green and black teas \nare processed differently during ma nufacturing. To produce green tea,  freshly harvested leaves are \nsteamed, yielding a dry, stable product. A typical tea beverage, prepared in  a proportion of 1 g leaf to  \n100 mL water in a 3 min brew, usually contains 250\u2013350 mg tea solids, comp rising 30%\u201342% catechins \nand 3%\u20136% caffeine [72].", "start_char_idx": 0, "end_char_idx": 3024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a074b39-5841-4264-8f48-1be7c0c91348": {"__data__": {"id_": "8a074b39-5841-4264-8f48-1be7c0c91348", "embedding": null, "metadata": {"page_label": "13", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "da442196-2381-49b8-90ce-0d40bfe337bf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "94c5c876d5c3ec2b6851a44d69499d1e3fcae647498915f64bc06c9f9c8e0c9e", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3658 \n \n3.8.1. Possible Mechanisms \nMost of the beneficial effects of tea are attributed to its polyphenolic flavo noids, known as catechins. \nThe major flavonoid is epigallocatec hin-3-gallate (EGCG). These polyph enols account for up to 40% of \nthe dry weight of green tea, and purified EGCG has been the focus of  research in recent years [73]. \n3.8.2. Observational Studies \nA population-based prospective coho rt study (the Ohsaki Study) included 40,530 persons  in Miyagi \nprefecture in northern Japan [74] . Risk for CVD mortality was found with increasing green tea \nconsumption (occasional, 1\u20132 cups/day, 3\u20134 cups/day, and 5 or more cups/day, when the volume of a \ntypical cup of green tea is 100 mL) was:  1.00, 0.84 (95% CI 0.63\u20131.12), 0.69 (95% CI 0.52\u20130.93), 0.69 \n(95% CI 0.53\u20130.90), respectively ( p for trend = 0.004). Within CVD mortality, the stronger inverse \nassociation was observed for stroke  mortality. A meta-analysis of 18 studies included 13 studies on \nblack tea and 5 studies on green tea. For black tea, no significant association was seen with the risk for \ndeveloping CAD. For green tea an in crease of 1 cup/day was associated  with a 10% decreased risk of \nCAD incidence (RR: 0.90, 95% CI: 0.82\u20130.99) [75]. In a meta-analysis of 194,965 pa rticipants in nine \nstudies, individuals consuming \u22653 cups of tea per day had a 21% lower risk of stroke than those \nconsuming <1 cup per day (absolute risk reduction, 0.79, 95% CI 0.73\u20130.85) [76]. \n3.8.3. Intervention Studies \nNo randomized controlled trial studied the eff ects of tea consumption on CVD morbidity or \nmortality; however, many studies eval uated the effects of tea on CV risk factors. More than half of the \nrandomized controlled trials have demonstrated the be neficial effects of green tea on CVD risk profiles. \nThese results suggest a plausible mechanism fo r the beneficial effects of green tea [75]. \nIn a meta-analysis of 133 trials, black tea cons umption increased systolic (5.69 mmHg; 95% CI \n1.52\u20139.86; 4 studies) and diastolic (2.56 mmHg; 95%  CI 1.03\u20134.10; 4 studies)  blood pressure, but \nchronic consumption did not appear to affect blood pressure. Green tea did not appear to  affect blood \npressure, but reduced LDL cholesterol levels ( \u22129 mg/dL; 95% CI \u22124.6, \u221213.1; 4 studies) [39]. Other \nsuggested mediators for the asso ciation between tea consumption and reduced CVD risks include \nanti-inflammatory, anti-oxidant, and an ti-proliferative effects, as well as favorable effects on endothelial \nfunction [77]. \n3.8.4. Adverse Effects  \nThere do not appear to be any significant side-e ffects or toxicity asso ciated with green tea \nconsumption. In general, the stimulatory effect from green tea is considerably less than that from coffee [78]. \nHowever, tea extract may cause gastrointestinal i rritation. Although there are a few case reports of liver \ntoxicity resulting from the ingestion of large quantities of green tea or green tea extract, the incidence of \nthis potential adverse effect appears extremely low. Since green tea may interfere with the absorption of \niron supplements, iron supplements should not be inge sted together with green  tea components. Possible \ninteractions between green tea and other me dications have also been reported [79].", "start_char_idx": 0, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1ce8045-808b-4cf6-9254-c5a3e1e5176a": {"__data__": {"id_": "e1ce8045-808b-4cf6-9254-c5a3e1e5176a", "embedding": null, "metadata": {"page_label": "14", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a116771d-514d-4b60-8024-d3503a4638ae", "node_type": "4", "metadata": {"page_label": "14", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "274b0b185714710ffac7492ff7e2f7ef78142d97620a3dc39ec41b7c9fe6f8dd", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3659 \n \n3.9. Chocolate \nCocoa is rich in polyphenols, similar to those found in green tea. Chocolate and cocoa are two \ndifferent things. Cocoa is the non-f at component of cocoa liquor (finel y ground cocoa beans) that is used \nin chocolate making or as cocoa powder (commonl y 12% fat) for cooking and drinks [80]. Fat  and sugar \nare major components of chocolate, which has high calor ic content that needs to  be taken into account \nwhen assessing possible risks and benefits of reco mmending chocolate consumption for health purposes. \nHowever, the major fatty acids in chocolate are olei c, palmitic, and stearic acids; oleic and stearic acids \nmay have a neutral effect on blood lipi d levels [81]. Chocolate, especial ly of the milk variety, contains \nlarge amounts of sugar and has possible implications for dental health and diabetes if eaten in large \nquantities, although carbohydrates might  play a role in improving uptake of polyphenols. Cocoa itself is \nmuch easier to recommend on a health basi s as it is not high in sugar and fat . \n3.9.1. Observation Studies \nA recent meta-analysis of seven observational studi es reported a beneficial association between \nhigher levels of chocolate consum ption and the risk of CVD. Th e highest levels of chocolate \nconsumption were associated with an adjusted lower risk for CVD (RR = 0.63 (95% CI 0.44\u20130.90) and a \n29% reduced risk stroke co mpared with the lowest levels [82]. However, most of the studies did not \nadjust for socioeconomic factors, which may confound this association. \n3.9.2. Intervention Studies and Possible Mechanisms \nMost of the existing evidence is on intermediate f actors of CVD. Recent studies (both experimental \nand observational) have suggested that chocolate consumption has a positive influence on human health, \nwith antioxidant, antihypertensive, anti-inflammator y, anti-atherogenic, and an ti-thrombotic effects as \nwell as influence on insulin sensitiv ity, vascular endothelial function, an d activation of n itric oxide [82]. \nDietary flavanols have also  been shown to improve endothelial f unction and to lower blood pressure by \ncausing vasodilation in the peripheral vasculature and in the brain [83]. \nDespite this array of benefits, there is a lack of  well-designed clinical st udies demonstrating a CV \nbenefit of chocolate. The high calori c content of chocolate, particularly  of some less pure forms, should \nbe considered before recomme nding uncontrolled consumption [84].  \n3.10. Garlic \nThe bulk of the dry weight of garlic ( Allium sativum ) contains mainly fructose-containing \ncarbohydrates, followed by sulfur compounds , protein, fiber, and free ami no acids. It also contains high \nlevels of saponins, a variety of minerals and vitami ns A and C, and a high phenolic content. Garlic has \nbeen attributed with favorable CV effects due to its high content of thiosulfinates, including allicin, \nwhich is considered to be the active component of garlic. Allicin is formed when alliin, a \nsulfur-containing amino acid, comes into  contact with the enzyme alliinas e when raw garlic is chopped, \ncrushed, or chewed. Over the years,  different garlic preparations ha ve been investigated for their \nprevention and treatment of CV disease, includi ng raw garlic, garlic powder tablets, oil of \nsteam-distilled garlic, oil of oil-m acerated garlic, ether-extracted oil of  garlic, and aged garlic extract.", "start_char_idx": 0, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46332af2-7ced-4675-9b08-b230b898202e": {"__data__": {"id_": "46332af2-7ced-4675-9b08-b230b898202e", "embedding": null, "metadata": {"page_label": "15", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "75ec51b9-be27-434e-b6df-d9f261ca2253", "node_type": "4", "metadata": {"page_label": "15", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "22c361c4375ca6d14fb731dd04d0cb8c9cdcc2579bfcde51bc6a8ff346bb02a5", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3660 \n \nAll these preparations differ in their composition, which complicates  comparison of studies [85].  \nDried garlic preparations containing alliin and alliin ase must be enteric coated to be effective because \nstomach acid inhibits alliinase. Because alliinase also  is deactivated by heat, cooked garlic is less \npowerful medicinally [86]. \nLong-term observation studies are missing. Interv ention trials focused on CVD risk factors. \nIn a meta-analysis of 29 trials garlic was found to significantly reduc e total cholesterol ( \u22120.3, 95% CI \n\u20132.3, \u201312.7 mg/dL) but exhibited no si gnificant effect on LD L-C or HDL-C levels [87]. However,  \nin a later meta-analysis of 13 trials there was no significant difference in effects on all outcome measures \nexamined when compared with placebo [88]. A revi ew of trials assessing th e effect of garlic on \nthrombotic risk showed modest but  significant decreases in platelet aggregation with garlic compared \nwith placebo [89]. The antihype rtensive effects of garlic have been studied but remain controversial [88]. \n3.10.1. Adverse Effects \nProven adverse effects include malodorous brea th and body odor. Other unproven effects included \nflatulence, esophageal and abdominal pain, allergic reactions, and bleeding [86] . \n3.10.2. Dosage \nThe effective dose of garlic has not been de termined. Dosages generally recommended in the \nliterature for adults are 4 g (one to two cloves) of raw garlic per day, one 300 mg dried garlic powder \ntablet (standardized to 1.3 percent alliin or 0.6 per cent allicin yield) two to three times per day, or 7.2 g \nof aged garlic extract per day [86]. \n3.11. Eggs \nDuring the past 40 years, the public had been warn ed against frequent egg consumption due to the \nhigh cholesterol content in eggs and the potential association with CVD [90]. This was based on the \nassumption that high dietary choleste rol consumption is associated wi th high blood chol esterol levels \nand CVD. However, subsequent research suggests that , in contrast to SFA and TFA, dietary cholesterol \nin general and cholesterol in eggs  in particular have limited effect s on the blood choles terol level and on \nCVD [91]. Eggs are also a source for high biological va lue protein, as well as vi tamins and minerals such \nas folic acid, vitamin B12, vitamins E and D, selenium, choline, zinc, etc. About 50% of the fat in the egg \nis MUFA [92]. \nLevel of evidence and classes of recommendations  for food items is summarized in Table 7.", "start_char_idx": 0, "end_char_idx": 2515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e0610a2-607a-43d7-84c8-c7a1afd961ac": {"__data__": {"id_": "4e0610a2-607a-43d7-84c8-c7a1afd961ac", "embedding": null, "metadata": {"page_label": "16", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "076164f0-a19f-4bde-9daa-2d063ab87c93", "node_type": "4", "metadata": {"page_label": "16", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "47076159d54109b0007a2833300a6bd6a5ba49b3450c170778284cd4532a6b9b", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3661 \n \nTable 7.  Level of evidence and classes of recommendations for food items. \nFood item Recommendations Strength Level of evidence \nWhole grains and dietary fiber The recommended dietary fiber intake is 14 g per 1000 kcal, or 25 g for adult women  \nand 38 g for adult men. II a B \n It is recommended to increase dietary fiber intake in order to reduce blood LDL-C  \nand glucose. I A \nVegetables and fruits It is recommended to consume at least 8 portions  of vegetables and fruits a day. Preferably \nroot vegetables and deep-colored fruits su ch as spinach, carrot, peach, and blueberries \n(since they usually contain more micronutrien ts compared to other vegetables and fruits).II a B \n It is recommended to eat the whole fruit rather  than fruit juice because of the fiber content \nand the satiation. II a A \n It is recommended to use cooking techniques such as saut\u00e9ing or simmering that preserve \nthe micronutrients in the vegetables and fruits  without additional calories, SFA, TFA, salt \nor sugar. II a A \n In cases of disease influenced by dietary carbohydrates, sodium, or potassium (diabetes, \nkidney, coagulation), vegetables and fruits  quantity should be personally adjusted. II a A \nNuts and almonds It is recommended to consume 20\u201330 g/day of unsalted nuts and almonds, or 150 g/week, \nas a substitute for other food (with equal caloric  content to prevent weight gain) in order to  \n improve blood lipids. II a A \n Reduce CVD risk. II a B \nMilk and dairy products It is recommended to include dairy products (preferably low-fat and without added sugar) \nas part of a balanced diet. II a B \n Low-fat milk and dairy products lower blood pressure. I A  There is epidemiologic data to suggest an association between dairy product consumption \nand reduced CVD. II a B \n At this stage, there is no evidence that ca lcium and/or vitamin D supplements prevent \nCVD (supplements may be taken for othe r indications such as osteoporosis). III C", "start_char_idx": 0, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbcde0a7-6aac-4fca-bee5-f240a7847d5e": {"__data__": {"id_": "bbcde0a7-6aac-4fca-bee5-f240a7847d5e", "embedding": null, "metadata": {"page_label": "17", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ed305f47-a111-4fe0-a483-79212d988b65", "node_type": "4", "metadata": {"page_label": "17", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "e0a85a67983686443ede4ed8eaef34d4f2ac71499cd47574f018556cf67a65d4", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3662 \n \nTable 7.  Cont.  \nAlcohol Due to the absence of interventional controlle d studies of moderate alcohol consumption \nwith clinical endpoints, there is no recommendation to start drinking alcohol for  health benefits. III C \n In individuals who regularly drink a modera te amount of alcohol (1 drink a day in \nwomen and 2 drinks per day in men) with meals, there is an associated reduced CVD incidence. Larger amounts should be discouraged. I B \n Individuals with liver disease and/or fatty liver, HTN, or hypertriglyceridemia, and \npregnant women should avoi d alcohol consumption. III B \n Alcohol drinking should be avoided before  driving and/or coordinated activity. III A \nCoffee In order not to increase CVD morbidity and mortality, and/or side effects, it is \nrecommended to consume the following amounts of caffeine:  Healthy adults without caffeine sensitivity: up to 400 mg/day;  Pregnant women: up to 200\u2013300 mg/day;  Children 4\u20136 years old: up to 45 mg/day. II a B \nGreen tea Green tea consumption is associated with a lo wer risk for stroke and CVD. However, the \ncausal effect and the dose needed for this effect is unknown. II a B \n Green tea consumption may reduce LDL-C; however, the effect-size and the dose \nneeded are still unknown. II b A \nChocolate It is not recommended to cons ume chocolate for CVD prevention. III C \n Dark chocolate, with a high cocoa percen t, has abundant antioxidants and therefore \npreferable over milk chocolate. II a B \nGarlic Eating 2 garlic cloves a day may marginally reduce blood cholesterol levels. II b C \nEggs Consumption of 5 eggs per week does not significantly increase CVD risk in  \nhealthy people. II a B \n In people with diabetes, CHD, and/or hypercholesterolemia that is not medically \nbalanced there may be an increased risk fro m egg consumption. It is recommended to \nlimit egg consumption to 3\u20134 per week, including eggs contained in other foods. II a B", "start_char_idx": 0, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c663f792-051a-418d-9568-d1c427515f74": {"__data__": {"id_": "c663f792-051a-418d-9568-d1c427515f74", "embedding": null, "metadata": {"page_label": "18", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9d035547-2b01-4fd6-936a-7a1f11fbb0c5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "3fe908e556e9c6d6544dceb016aa25cadb1ba3026bda4978a0f4b97838be644b", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3663 \n \n3.11.1. Observational Studies \nThe epidemiologic evidence relating egg-consumption to coronary disease risk is not entirely \nconsistent. Most large population st udies did not find an association between egg consumption and  \nCVD [93\u201395]. However, da ta from 20,000 men over 20 years follo w up in the Physicians\u2019 Health Study \nhave shown that egg consumption of at least 7 per w eek was associated with an increased risk of heart \nfailure (HF). Compared with subj ects who reported egg consumption of  <1 per week, hazard ratios for \nHF were 1.28 (95% CI 1.02\u20131.61) and 1.64 (95% CI 1.08\u20132.49) for egg consumption of 1 per day and  \n\u22652 per day, respectively [96]. Although egg consumption wa s not associated with in cident MI or stroke \nin a multivariate Cox regression in this study, adjusted HRs (95% CI) for mortality were  \n1.0 (reference group), 0.94 (0.87\u20131.02), 1.03 (0.95 \u20131.11), 1.05 (0.93\u20131.19), and 1.23 (1.11\u20131.36) for the \nconsumption of <1, 1, 2\u20134, 5\u20136, and \u22657 eggs/week, respectively ( p for trend < 0.0001) [97]. In several \nstudies, consumption of at least 5 eggs per week wa s associated with CVD and mortality in people with \ndiabetes [98]. \n3.11.2. Intervention Studies \nIn a meta-analysis of 17 interv ention studies lasting at least 14 days, th e addition of 100 mg  \ndietary cholesterol per day increased cholesterol le vels by 2.2 mg/dL, while HDL-C also increased by  \n0.3 mg/dL [99]. \n3.11.3. Biological Mechanisms \nThere is a great variation in the response of blood choleste rol levels to dietary cholesterol, possibly \nrelated to the large variability in intestinal absorpti on of cholesterol. It is also possible that the fat \ncomposition of eggs (high MUFA and lower SFA ) restrains the blood LD L-C elevation [100]. \n4. Nutritional Supplements \n4.1. Salt and Sodium \nA low-sodium diet fits all dietary strategies. Diet ary sources for sodium include: table salt, soups and \ngravies, soy and other sauces , salad dressing, industrial ly prepared meat (such as  salami or industrialized \nfrozen meat), cheese, snacks such as pretzels and popcorn, pickled foods and industrialized food in \ngeneral (health services information). On average, as  dietary salt (sodium chlori de) intake rises, so does \nBP. Evidence includes results from animal studies , epidemiological studies, clinical trials, and \nmeta-analyses of trials. In a meta-analysis in cluding a total of 17 trials in hypertensives ( n = 734) and  \n11 trials in normotensives ( n = 2220), a median reductio n in urinary sodium of \u22481.8 g/day lowered  \nsystolic BP and diastolic BP by 2.0 and 1.0 mmH g in nonhypertensive and by 5.0 and 2.7 mmHg in \nhypertensive individuals [101]. A recent Cochrane database review summarized three studies in \nnormotensives ( n = 3518), two in hypertensives ( n = 758), one in a mixed population of normo- and \nhypertensives ( n = 1981), and one in heart failure ( n = 232) with end of tria l follow-up of seven to  \n36 months and longest observational follow up (after trial end) of 12.7 years. Reduction of salt intake \nwas not associated with CVD morbidity or all-caus e mortality in general, and paradoxically increased", "start_char_idx": 0, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4dbfff4-40a6-4636-a304-3653b5b3a892": {"__data__": {"id_": "c4dbfff4-40a6-4636-a304-3653b5b3a892", "embedding": null, "metadata": {"page_label": "19", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c908c086-bda0-45ae-b975-e2a4e5192787", "node_type": "4", "metadata": {"page_label": "19", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "b34fe60485672a6dbeb33669bf6332bcdbc573008c5c4610cd95f1c93521e265", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3664 \n \nthe risk of all-cause death in those with congestive heart failu re (end of trial RR = 2.59, 95% CI \n1.04\u20136.44, 21 deaths) [102]. Despite these results, the au thors concluded that the sample size had \ninsufficient power to exclude clinically important effects of reduced dietary salt on mortality or CV \nmorbidity in normotensive or hypertensive populations. Recently, the Institute of Medicine committee concluded that, although sodium restriction is reco mmended, evidence from studies on direct health \noutcomes is inconsistent and insu fficient to conclude that loweri ng sodium intakes below 2300 mg per \nday either increases or\n decreases risk of CVD outcomes (inc luding stroke and CVD mortality) or \nall-cause  mortality in the general U.S. population  [103].  \n4.2. Antioxidant Vitamins E and C \nWhile being supported by observational studies, ra ndomized controlled trials  have not supported a \nrole for vitamins in the primary or secondary prevention of CVD, and have in some cases even indicated \nincreased mortality in those with pre-existing late-sta ge atherosclerosis. In a meta-analysis of 56 trials \nwith a low risk of bias, the antioxidant supplemen ts modestly increased mortality (RR = 1.04, 95% CI \n1.01\u20131.07). In intervention trials  including vitamins A, C, E, beta- carotene, and selenium, no beneficial \neffect was detected on all caus e mortality in secondary preventi on. Vitamin A, beta-carotene, and \nvitamin E supplementation increased total mortality (RR = 1.06, CI 95% 1.04\u20131.10) [104]. \nStudies have also indicated that beta-carotene mediates pro-oxidant effects. The trials that used a \ncombination of vitamins that include beta-carotene have been disappointing. St udies also suggest that \nvitamins would be beneficial to individuals who ar e antioxidant-deficient [105] . A recent trial reported \nthat consumption of a multivitamin had no effect on CVD risk in men [106]. \n4.3. Vitamin D \nThe association between vitamin D and bone disease is well established. However, vitamin D has \nmany other functions and the use of vitamin D supplements to prevent and treat a wide range of illnesses \nhas increased substantially over the last decade. Epid emiologic evidence links vitamin D deficiency to \nautoimmune disease, cancer, CVD, depression, dementia , infectious diseases, mu sculoskeletal decline, \nand more [107]. \nA diet high in oily fish prevents vitamin D deficiency. Solar ultraviolet B radiation penetrates the skin \nand converts 7-dehydrocholesterol to pre-vitamin D 3, which is rapidly converted to vitamin D 3 [108]. \nFortified milk with vitamin D is also a source for vitamin D. \n4.3.1. Observation Studies \nIn a meta-analysis of five prospective cohort st udies, the RR for CV events was 1.34 (95% CI \n1.08\u20131.67) during an average follow up of 11.8 years [1 09]. A meta-analysis supported an overall \nassociation of 25-OH-D baseli ne levels in the lowest compared to the highest categories, with CV events \n(pooled HR = 1.54, 95% CI 1.22\u20131.95) [110]. A meta-analy sis of 90 prospective st udies demonstrated a \nlinear inverse associatio n between blood 25-(OH)-vitamin D ra nging 20\u201360 nM/L and CVD risk [111].", "start_char_idx": 0, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b98b919b-f0b5-46fc-92ee-b58412bdb893": {"__data__": {"id_": "b98b919b-f0b5-46fc-92ee-b58412bdb893", "embedding": null, "metadata": {"page_label": "20", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a9dbf832-4334-4668-ab56-7c9c889a92c0", "node_type": "4", "metadata": {"page_label": "20", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "bee1a589ae99b0418c2581e8e62b2f27d40523ea66221c00b4cd27da1a7236b5", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3665 \n \n4.3.2. Randomized Trials \nIn a meta-analysis of osteoporosis intervention trials, f our trials (in five articles)  reported the effect of \nvitamin D supplementation on incident CVD. None repor ted a statistically significant effect of vitamin \nD supplementation (with or without calcium) on myocar dial infarction, stroke , and other cardiac and \ncerebrovascular outcomes. Study participants were fo llowed for 1, 5, or 7 year s. The Women\u2019s Health \nInitiative trial performed 12 analyses of different  CV outcomes, and reported a near statistically \nsignificant harmful effect with combined vitami n D and calcium supplementation on one composite \ncardiac outcome that included non-fatal myocardial infa rction, coronary heart di sease death, or need for \nrevascularization (RR = 1.08; 95% CI 0.99\u20131.19) [112]. \nIn summary, at this time no reco mmendations can be made for vitamin D screening or treatment in \npopulations without risk for bone fractures, for the sa ke of preventing CVD. Fu rther investigation is \nneeded to find whether treatment for vitamin D de ficiency can reduce CVD morbidity and mortality. \n4.4. Coenzyme Q10 \nCoenzyme Q10 (CoQ10) is a naturally occurring, fa t-soluble quinone that is  localized in hydrophobic \nportions of cellular membranes and acts as an electron carrier in the mitochondrial respiratory chain [113]. \nIt also functions as an antioxidant, scavenging fr ee radicals and inhibiting lipid peroxidation [114]. \nClinical studies have focused on three potential effects of CoQ10 supplemen tation: congestive heart \nfailure, hypertension (HTN), and myopa thy related to statin therapy. \nIn different CVDs, including cardiomyopathy, relative ly low levels of CoQ10 in myocardial tissue \nhave been reported. However, in a sub-analysis of 1191 patients with  ischemic systolic heart failure \nenrolled in the CORONA study, rosuvastatin reduced  CoQ10, but even in patients with a low baseline \nCoQ10, rosuvastatin treatment was not associat ed with a significantly worse outcome [115].  \nIntervention Studies \nFavorable short-term clinical and hemodynamic e ffects of oral CoQ10 supplementation have been \nobserved in double-blind trials, espe cially in people with HTN and ch ronic heart failure. There have \nbeen no important adverse effects reported from e xperiments using daily supplements of up to 200 mg \nCoQ10 for 6\u201312 months and 100 mg daily for up to 6 years [116]. \nIn a meta-analysis of 12 trials, ejection fraction was evaluated in 10 studies ( n = 277) and cardiac \noutput in two studies ( n = 42). Doses ranged from 60 to 200 mg/day  with treatment pe riods ranging from \n1 to 6 months. There was a 3.7% net improvement in ejection fraction [117]. However, the long-term \neffect of this supplementati on on clinical outcome is unknown. \nIn a meta-analysis of five trials including 194 pa tients, treatment with co enzyme Q10 significantly \nimproved endothelial function as assessed peripherally by flow-m ediated dilatati on (SMD 1.70, 95% \nCI: 1.00\u20132.4, p < 0.0001). However, the endo thelial function assessed peri pherally by nitrate-mediated \narterial dilatation was not significantly improved [118]. \nIn a meta-analysis of three trials assessing treatment with CoQ10 in subjects with systolic  \nBP > 140 mmHg and diastolic BP  > 90 mmHg, there was a significant reduction of 11 (95% CI  \n8\u201314) mmHg and 7 (95% CI 5\u20138) mmHg, respectively. However, the authors conclude that due to the", "start_char_idx": 0, "end_char_idx": 3465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aefacea-a52e-4e93-a138-815c45a2aac9": {"__data__": {"id_": "6aefacea-a52e-4e93-a138-815c45a2aac9", "embedding": null, "metadata": {"page_label": "21", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2de40199-8596-47f5-8203-98e24286a7c7", "node_type": "4", "metadata": {"page_label": "21", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "6c14fef4774e49a6d79a10be35f5e6841a15bcaecf186ad751f64f07c2a40e63", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3666 \n \npossible unreliability of some of the included studies, it is uncerta in whether or not CoQ10 reduces \nblood pressure in the long-term ma nagement of primary HTN [119]. \nStatins inhibit 3-hydroxy-3-methylgl utaryl coenzyme A (HMG-CoA) re ductase, blocking cholesterol \nsynthesis at a step that not only reduces choles terol synthesis but also the production of other \nmetabolites, including ubiquinone CoQ10. Statins reduce plasma/serum levels of CoQ10 16% to 54%, \nmainly as a result of reducing serum LDL, which is its major transporter [120]. The effects of statins on \nskeletal muscle with CoQ10 supplementation were inconsistent. Supplementation of CoQ10 increases \nthese levels [121]. However, the e ffect of CoQ10 supplementation on pa tients with statin myopathy is \ninconsistent, and recent randomized trials of coen zyme Q10 supplementation have shown conflicting \nresults [121].  \n4.5. Magnesium \nMagnesium (Mg) is an abundant intracellular mineral in the body. A pproximately 50% of total body \nMg is found in bone. Only 1% of Mg  is found in serum, and it remains constant within a wide range of \nintake levels. Therefore, Mg stat us is difficult to determine from  serum Mg measurements [122].  \nDietary sources of Mg are green leafy vegetables (p articularly spinach), nuts,  avocados, whole grains, \nlegumes (beans and peas), soy beans, chocolate, and some seafood [123]. The recommended daily intake \nis 420 mg/day for men and 320 mg/day for wome n. Maximum recommende d daily intake from \nsupplements is 350 mg/day of elemental Mg, ba sed on Dietary Referenc e Intake (DRI) [123]. \n4.5.1. Observational Studies \nObservational epidemiological studies have shown th at the Mg content of dr inking water and food is \ninversely related to morbidity and mortality from heart disease and stroke [124 \u2013126]. \nThe highest quartile compared with  the lowest quartile of Mg da ily intake (a difference of  \n100 mg/1000 kcal/day between highest and lowest qua rtiles) was associated with a significant 31% \nreduction of the metabolic syndrome: HR = 0.69 (95% CI 0.52 \u20130.91; p for trend <0.01) [127]. \n4.5.2. Intervention Studies \nRelatively small studies have show n a distinct advantage in providi ng Mg versus pl acebo on reducing \nmortality in patients with acute MI ; however, two major stud ies published in recent years have failed to \nprove this [128]. \nIntervention studies have indicat ed that Mg supplementation was effective in pa tients with  \nheart failure receiving diuretic th erapy that reduces both Mg and pot assium levels [ 129]. Oral Mg  \n(365\u20131200 mg/day for 3 \u20136 months) improved endothelial  function [130] and inhi bited platelet-dependent \nthrombosis in patients with CAD [131]. \n4.5.3. Conclusions  \nThe effect of Mg on the primar y and secondary prevention of CV  morbidity and mortality as  \nwell as all-cause mortality remains unclear, and ther efore it is not yet possible to give conclusive \nrecommendations in this respect.", "start_char_idx": 0, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b1d6d1b-6f1e-4b10-b9ae-5d8d20868c39": {"__data__": {"id_": "3b1d6d1b-6f1e-4b10-b9ae-5d8d20868c39", "embedding": null, "metadata": {"page_label": "22", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "595d2b25-1048-4cda-8533-b59b1768ec7c", "node_type": "4", "metadata": {"page_label": "22", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "df69852708d82630e33ea6cc4b741cc2f2e074166692d5b2a9518c5885c5c1e2", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3667 \n \n4.6. Homocysteine-Reducing Agents \nHomocysteine is an amino acid that contains sulf ur and is produced in the body during the breakdown \nof the amino acid methionine. Part of the homocysteine formed in this process is recycled back to build \nmethionine, while the rest is excreted in the urin e. Folic acid, vitamin B12, and vitamin B6 regulate the \nmetabolism of homocysteine. Deficien cies of one of these vitamins can  lead to high blood homocysteine \nlevel. The normal range of  blood homocysteine is 5 \u201315 mM/L [132]. Major food sources of folic acid \nare: chicken liver, leafy green vege tables (spinach, broccoli, lettuce,  kale, Swiss chard), beans (dried \nlentils, chickpeas), enriched flour, citrus fruits (mainly oranges), fo rtified cereals, and wheat germ.  \nFood sources for vitamin B12 include animal products : beef, chicken, fish, egg yolk; dairy products;  \nand fortified foods (such as cereals). Women of ch ildbearing age should consume 400 mcg/d of folic \nacid for the prevention of neural tube defects of the fetus [133]. \n4.6.1. Observation Studies \nIn many studies, high homocysteine le vels are associated with increas ed risk of MI and/or stroke. \nSince folic acid, B 12, and B6 (separately and combined) decr eased the blood homocysteine level in \n20%\u201340%, from baseline, it has been postulated that  these supplements, can subsequently reduce  \nCVD risk [134]. \n4.6.2. Intervention Studies \nThe effectiveness of folic acid  and B vitamin supplementation  was examined mainly in secondary \nprevention intervention studies. Thes e studies failed to prove that re ducing homocysteine level by folic \nacid and vitamin B supplements improves CVD inci dence [134]. In the Norwegian Vitamin Trial \n(NORVIT), the RR of re-infarction in cidence, stroke, or sudden death in the group receiving 0.8 mg folic \nacid, 0.4 mg vitamin B12, and 40 mg Vitamin B6 co mpared to a control group was: 1.22, 95% CI \n1.00\u20131.50; p = 0.05 [135]. The effect in primary and seconda ry prevention of stroke was minimal,  \nas shown in a meta-analysis of 13 trials and 39,005 participan ts. The risk of stroke in those taking folic \nacid and vitamins B12 and B6 was RR = 0.83, 95% CI 0.71 \u20130.97 [136]. A meta-analysis of folic acid \nsupplementation in patients with chr onic kidney disease also failed to  show a beneficial effect in \ncardiovascular outcome [137].  \n4.7. Omega-3 and Fish Oil \nPolyunsaturated fatty acids are characterized a ccording to the position of the first double bond.  \nIn omega-3 (also called \u03c9-3 or n-3) fatty acids the first double bond is situated after the third carbon \natom from the methyl end of the carbon chain. Hu mans cannot synthesize short-chain fatty acids and \ntherefore need to consume them in their diet. They  include the plant-derived alpha-linolenic acid (ALA, \n18:3n-3), and the fish-oil-derived ei cosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid \n(DHA, 22:6 n-3).", "start_char_idx": 0, "end_char_idx": 2948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b3edaa-8624-4d94-bd78-628d5f5e3443": {"__data__": {"id_": "c3b3edaa-8624-4d94-bd78-628d5f5e3443", "embedding": null, "metadata": {"page_label": "23", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2abe2a1d-9183-4862-864a-f2fc074aed8d", "node_type": "4", "metadata": {"page_label": "23", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "9b37b4f3145110da253512b2068d1d635bd8bb8884892ec4fd80c7a7f3a0d115", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3668 \n \n4.7.1. Dietary Sources \nALA is found in seeds, vegetabl e oils (especially canola and flax seed), green leafy vegetables, \nwalnuts, and beans. Although some ALA can be tr ansformed in the human body to EPA and DHA, such \nconversion appears to be inefficient [138], and the majo rity of these fatty acids are consumed from cold \nwater oily fish, such as salmon, herring, mackerel, anchovies, tuna, and sardines. \n4.7.2. Omega-3 Supplements \nVarious sources of omega-3 fatty acids are used as supplements fo r commercial use, including fish \noil, flaxseed oil, and walnut oil. Although the F DA has concluded that omega-3 dietary supplements \nfrom fish are \u201cgenerally recognized as safe\u201d, some have questioned the safety of fish oil supplements \nbecause some species of fish can contain high leve ls of mercury, pesticides, or polychlorinated \nbiphenyls (PCBs). Most fish oil supplements under go purification processes and do not appear to \ncontain these substances in appreciab le quantities. Many clinical trials ha ve used an ethyl-ester form of \nomega-3 fatty acids, which may affect the product \u2019s bioavailability and metabolism [139]. Commonly \nused doses of omega-3 supplements (up to 1 g daily ) do not appear to have significant side effects. \nHowever, larger doses may cause minor gastrointestin al upsets, worsening of glycemia control, and a \nrise in LDL-C levels [140].  \n4.7.3. Observational Studies \nMost observational studies show an  inverse correlation between fish  consumption and cardiovascular \nCVD. A review of 11 cohort studie s involving 116,764 individua ls suggested that fish consumption at \n40\u201360 g daily is associated with markedly reduced CHD mortality in high-risk, but not in low-risk \npopulations [141]. \n4.7.4. Intervention Studies \nA meta-analysis of intervention trials including 7951 individuals treated with  omega-3 compared to \n7855 controls found a significant decrease in morta lity from MI but not in non-lethal MI [142].  \nIn another meta-analysis of 97 studies using different  types of lipid management strategies, the most \neffective combination was that of statins with omeg a-3, which resulted in a relative-risk reduction of \n23% in total mortality (RR = 0.77, 95% CI 0.63\u20130.94) a nd 32% in cardiac mortal ity (RR = 0.68; 95% CI \n0.52\u20130.90) [143]. However, more recent studies looking at the benefit of omega-3 treatment in high-risk \npatients (CHD and/or diabetes mellitus) receiving optimal medical therapy, in cluding statins, have \nshown mixed results with some showing significant benefit [144] while others  show little additional \nbenefit [145\u2013147]. Recent meta-analyses of randomized controlled tria ls found little evidence of a \nprotective effect of omega-3 s upplementation on the incidence of  CVD [148], cerebrovascular  \ndisease [149], or atrial fibri llation [150]. In a meta-analysis of  20 studies of 68,680 patients (13 on \nsecondary prevention), omega-3 PUFA supplementati on was not associated wi th a lower risk of \nall-cause mortality, cardiac death, sudden death, myocardial infarction, or stroke based on relative and \nabsolute measures of association. [151].", "start_char_idx": 0, "end_char_idx": 3160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3593cd51-54ef-4a72-9632-0183a9c3a728": {"__data__": {"id_": "3593cd51-54ef-4a72-9632-0183a9c3a728", "embedding": null, "metadata": {"page_label": "24", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f0d1f3f5-6bbf-43bb-a474-bbc09a4335bf", "node_type": "4", "metadata": {"page_label": "24", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "677b31b2e4f3bf57a5ef5a428ad5ac86b1451a491da8d9e02dfabb6061d0bd9a", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3669 \n \n4.7.5. Possible Mechanisms \nThe long-chain omega-3 fatty acids EPA and DHA compete with arachidonic acid (a long chain \nomega-6 fatty acid) in the synthesis of prostagla ndins and leukotrienes invol ved in inflammation and \nthrombogenesis. Omega-3 fatty acids have been shown to in crease arrhythmic thre sholds, reduce blood \npressure, improve endothelial function, reduce infla mmation and platelet aggregation, enhance plaque \nstabilization, and favorably affect autonomic tone [ 152]. At high doses (2\u20136 g daily) they can \nsignificantly reduce the serum triglyceride levels, but the long-term clinical outcome of such treatment \nin hypertriglyceridemic individuals  has not been evaluated [153]. \n4.8. Phytosterols \nSterols constitute an important constituent of plan t cellular membranes, in a manner similar to the \nrole of cholesterol in human cells  [154]. They are found at low concen trations in most plant-derived \nnutrients but at somewhat higher concentrations in so me grains. Despite their structural similarities to \ncholesterol, plant sterols are not synthesized in the human body and are only minimally absorbed from \nthe human intestinal tract. The average western diet  contains approximately 200\u2013500 mg of cholesterol, \napproximately 200\u2013400 mg of plant st erols, and 20\u201350 mg of plant stanols. Amongst the best known \nplant sterols are sitosterol , campesterol, and stigmasterol. Those that  are incorporated in food are usually \nesterified. Hydrogenation converts st erols into stanols (e.g., sitostanol and campestanol), which can also \nbe esterified. \n4.8.1. Intervention Studies \nEvaluation of intervention studies with sterol este rs and stanol esters suggest a reduction in LDL-C \nlevel of approximately 10%, without specific differences  between the type of st erol or stanol or the \nmethod by which it was administered (immersed in a f ood product or as a separa te supplement) [155\u2013158]. \nSimilar results were obtained in the different popul ations studied (children, he althy adults, or patients \nwith diabetes and/or CHD) [159,160]. The optimal dos e appears to be 1.5\u20132.5 g/ day, with no additional \nbenefit at higher doses [161]. Add ition to statins resulted in a further 10% reduc tion in LDL-C beyond \nthat achieved with the statins alone [162]. To date , no long-term intervention studies of sterol/stanol \ntreatment evaluating clinical endpoints have been published. \n4.8.2. Possible Mechanisms \nDue to their biochemical similari ty, plant sterols and st anols can displace cholesterol from mixed \nmicelles in the intestine, thus reducing the absorp tion of dietary cholestero l [163]. Although they have \nsignificant atherogenic potential, the intestinal absorption of sterols and stanols is poor, resulting in very \nlow serum concentrations. An exception to this rule  is patients with sitosterolemia, a rare genetic \ndisorder in which the absorp tion of sterols is enhanced, resulting in  significant damage to various organs. \nLevel of evidence and classes of recommendations for nutritional supplements is summarized in \nTable 8.", "start_char_idx": 0, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d00c419-4793-4f26-90f3-d1c6904a0287": {"__data__": {"id_": "3d00c419-4793-4f26-90f3-d1c6904a0287", "embedding": null, "metadata": {"page_label": "25", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9764b622-a0f5-455f-86b2-448bccb6f9c8", "node_type": "4", "metadata": {"page_label": "25", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "28322e01d271e3224b1f99a9df76f1f96f8c74f0698dd8190f06e857b75c541b", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3670 \n \nTable 8.  Level of evidence and classes of r ecommendations for nutritional supplements.  \nSupplement  Recommendations Strength  Level of evidence  \nSodium  It is recommended to limit salt intake to 2.3 g sodium (6 g/day salt). It is \nrecommended to substitute salt with othe r spices and herbs. It is recommended \nto use food labels for information of sodium content in foods.  I B \n It is recommended to reduce as much as possible the use of industrial pre-prepared food, as well as salted snacks and vegetables.\n I B \n Efforts should be put into reducing s odium content in industrial foods  \nthrough legislation.  I B \nOmega-3     \nGeneral population (primary prevention)  Eat a variety of fish, preferably fat, at least twice a week. Each fish portion \n(55\u201385 g) should supply at least 500\u20131000 mg EPA + DHA.  II a A \nIt is recommended not to exceed 200 g daily of fish that contain a high level of mercury (such as mackerel, sword fish or shark) or 400 g of other fish. Removing the skin off the fish before  preparation can reduce the amount  \nof contaminants.\n I B \nFor children and pregnant women it is recommended to avoid eating fish with \npotentially high levels of contaminants.  III B \nOmega-3 supplements containing 1 g of EPA + DHA.  II b B \nPeople with proven CVD  Individuals who do not regularly cons ume fish might consider ingesting \nomega-3 supplements containing 1 g of EPA + DHA.  II b A \nHypertriglyceridemia  2\u20136 g of omega 3 daily can reduce serum  TG levels. However, no long-term \nstudies have been conducted to evaluate the clinical outcome in  these individuals\n II b B \nPhytosterols  Plant phytosterols can be considered for the reduction of LDL cholesterol in \nmildly hypercholesterolemic individuals at intermediate to high risk who do \nnot wish to use, or cannot tolerate, other cholesterol-lowering medications.  II a A \nPlant phytosterols can be used in co mbination with statins for additional \nreduction of LDL cholesterol.  II b A", "start_char_idx": 0, "end_char_idx": 1997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa4c8e04-9869-4cfa-8f8c-69c4f2491505": {"__data__": {"id_": "fa4c8e04-9869-4cfa-8f8c-69c4f2491505", "embedding": null, "metadata": {"page_label": "26", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07168dc4-6b65-4ea3-bcba-263687653332", "node_type": "4", "metadata": {"page_label": "26", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "3370e8af24ef82b8a520acf52dd256c08d8fd0186de4c043be6802260ae5c20b", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3671 \n \nTable 8.  Cont.  \nAntioxidant-vitamin supplementation  Based on data from intervention controlled  trials, it is not recommended to use \nantioxidant vitamins supplementation to prevent or treat CVD.  III A \nVitamin D  At this point there is no recommendation for screening blood vitamin D levels for CVD prevention.\n III C \n Correction of low vitamin D levels may reduce CVD morbidity and mortality.  II b B  \n It is not recommended to use vitamin D supplements in order to prevent CVD \nin people with normal vitamin D levels.  III C \nCoQ10  The long term effect of CoQ10 supple mentation on Patients with CHF and/or \ntreated with statins is yet to be proven . Therefore it is not recommended to use \nCoQ10 supplementation in these patients.  III B \n In the short term Co Q10 supplementation results in mild blood pressure \nreduction and mild increase in ejection fraction in CHF patients.  II b B \nMagnesium (Mg)  At this point there is no recommendation for screening blood magnesium levels for CVD prevention in general population.\n III C  \n Correction of low magnesium levels may reduce CVD morbidity and \nmortality, particularly after myocardial infarction.  II a A \n It is not recommended to use magnesium supplements in order to prevent CVD \nin people with normal magnesium levels.  III A \nFolate, vitamin B6, vitamin B12  Low serum folate and/or vitamin B12 c oncentrations should be corrected to \nprevent neurologic and hematologic diseases.  Women of childbearing age should consume 400 \u00b5g/day of folic acid supplementation for the prevention of neural tube defects of the fetus.\n I A  \n Folic acid and vitamin B supplements are not effective for primary, nor for \nsecondary prevention of CVD and stroke.  III A", "start_char_idx": 0, "end_char_idx": 1748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8673c0e3-8c3c-44fd-bc35-4d1179863d4c": {"__data__": {"id_": "8673c0e3-8c3c-44fd-bc35-4d1179863d4c", "embedding": null, "metadata": {"page_label": "27", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5adf154b-4e1e-40c6-9f46-002e60ddc559", "node_type": "4", "metadata": {"page_label": "27", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "cde4b9758b508b9c91073d4ac397efa522c4d0d53acda4a8d6b552ed5b455bf5", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3672 \n \n4.8.3. Safety \nSterol supplementation at the recommended doses is generally considered safe [164]. However, \nseveral potential risks need to be considered. In a ddition to inhibiting cholesterol absorption, some \n(though not all) studies suggest  that sterols and stanols can reduce th e blood levels of antioxidants such \nas lycopene and beta-carotene. [157,165]. This can be counteracted, at least partly, by the ingestion of a \ndiet reach in vegetables and fruits [166]. Despite the low serum concentration of sterols and stanols, \nsome concern has been raised that even the slight increase associated with dietary supplementation of \nsterols might increase the risk  for atherosclerosis [167]. \n5. Conclusions \nA healthy diet should include diversity  of foods and to maintain a heal thy weight. It is  preferable to \neat fresh or frozen food without a dditional sugar, salt or high-calor ie gravies, using cooking methods \nthat retain the original nutrients  undestroyed. It shoul d contain a variety of vegetables and fruits, \nlegumes, whole grains, whole wheat bread and hi gh-fiber low-salt food items. Vegetable oils, \n(especially olive and canola oils, ex cluding palm and coconut oils), shoul d be preferred over animal fat. \nAdditional elements that may confer  health benefits include avocado, nuts, almonds and tahini, low-fat \ndairy products, green tea and 2 to 3 servings of fa tty fish per week. It is recommended to minimize \nconsumption of high-fat meat (especially processe d meats that are high in fat and sodium), hard \nmargarines and pastries with hydrogenated fat, and f oods that are high in sodium and sugar. It is \nrecommended to drink a lot of water, and reduce cons umption of sweetened beverages as well as fresh \njuices. The Mediterranean diet has been shown to reduce cardiovascular morbidity and mortality in both \nprimary and secondary prevention. Other dietary pattern s that have been shown to confer advantage in \nspecific medical situations include low-fat diet for individuals at high cardiovascular risk,  \nDASH diet for people with hypertension, and low-carbohyd rate diets for overweight people and for the  \nmetabolic syndrome. \nConflicts of Interest \nSigal Eilat-Adar serves as a scie ntific consultant for the dairy i ndustry and has given lectures on \nbehalf of a number of companie s in the food and pharmaceutical industry, including some on cereals, \nmilk and milk products, tea, nut s, and nutritional supplements. \nTali Sinai and Chaim Yosefy decl are no conflicts of interest. \nYaakov Henkin serves as a scientif ic consultant, and has given lect ures on behalf of a number of \ncompanies in the food and pharmaceutic al industry, including some that are involved in the distribution \nof cereals, milk products, tea, chocol ate, wine, and nutritional supplements.", "start_char_idx": 0, "end_char_idx": 2841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a23d123d-75c1-4a8e-b33c-d5398a638145": {"__data__": {"id_": "a23d123d-75c1-4a8e-b33c-d5398a638145", "embedding": null, "metadata": {"page_label": "28", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "14061b51-3fd6-463c-9b1d-53a4e0bf6fb4", "node_type": "4", "metadata": {"page_label": "28", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "cc180752e12c25a721cb47886e7d8b042beb551bd43c39c28f3550a91a68c3f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e085de5d-e30a-4739-ade6-6bb8d0f177e4", "node_type": "1", "metadata": {}, "hash": "935ca959cc8ca7ec276af24349bff8f3e8712c8601097b22040722d689d3ffc8", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3673 \n \nReferences \n1. Ryd\u00e9n, L.; Stand, L.E.; Bartnik, M.; van den Berghe, G.; Betteridge, J.; de Boer, M.J. ; Cosentino, F.; \nJ\u00f6nsson, B.; Laakso, M.; Malmberg, K.; et al . Guidelines on diabetes, pre-diabetes, and \ncardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular \nDiseases of the European Society of Cardiology  (ESC) and of the European Association for the \nStudy of Diabetes (EASD). Eur. Heart J.  2007 , 28, 88\u2013136. \n2. Perk, J.; de Backer, G.; Gohlke, H.; Graham, I.; Reiner, Z.; Verschuren, M.; Albus, C.; Benlian, P.; \nBoysen, G.; Cifkova, R.; et al . European Guidelines on Cardi ovascular Disease Prevention in \nClinical Practice (version 2012). Th e Fifth Joint Task Force of the European Society of Cardiology \nand Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by \nrepresentatives of nine soci eties and by invited experts). Eur. Heart J.  2012 , 33, 1635\u20131701. \n3. American Heart Association Nutrition Committee; Lichtenstein, A.H.; Appel, L.J.; Brands, M.; \nCarnethon, M.; Daniels, S.; Franch, H.A.; Fra nklin, B.; Kris-Etherton, P.; Harris, W.S.; et al .  \nDiet and lifestyle recommendations revision 2006: A scientific stat ement from the American Heart \nAssociation Nutrition Committee. Circulation  2006 , 114, 82\u201396. \n4. Hooper, L.; Summerbell, C.D.; Thom pson, R.; Sills, D.; Roberts, F.G. ; Moore, H.J.; Davey Smith, G. \nReduced or modified dietary fat fo r preventing cardiovascular disease. Cochrane Database  \nSyst. Rev . 2012 , 5, CD002137. \n5. Hite, A.H.; Berkowitz, V.G.; Berkowitz, K. Low- carbohydrate diet review: Shifting the paradigm. \nNutr. Clin. Pract.  2011 , 26, 300\u2013308. \n6. Nordmann, A.J.; Nordmann, A.; Briel, M.; Keller, U. ; Yancy, W.S., Jr.; Brehm, B.J.; Bucher, H.C. \nEffects of low-carbohydrate vs. low-fat diets on weight loss and cardiovascular risk factors. A \nmeta-analysis of randomized controlled trials. Arch. Intern. Med. 2006 , 166, 285\u2013293. \n7. Santos, F.L.; Esteves, S.S.; da Costa Pereira, A.; Yancy, W.S., Jr.; Nunes, J.P. Systematic review \nand meta-analysis of clinical trials of the eff ects of low carbohydrate diet s on cardiovascular risk \nfactors. Obes. Rev.  2012 , 13, 1048\u20131066. \n8. Shai, I.; Schwarzfuchs, D.; Henkin, Y.; Shahar, D.R.; Witkow , S.; Greenberg, I.; Go lan, R.; Fraser, D.; \nBolotin, A.; Vardi, H.; et al. Weight loss with a low-carbohydrate,  mediterranean, or low-fat diet. \nN. Engl. J. Med. 2008 , 359, 229\u2013241. \n9. Trichopoulou, A.; Lagiou, P. Health y traditional Mediterranean di et: An expression of culture, \nhistory, and lifestyle. Nutr. Rev . 1997 , 55, 383\u2013389. \n10. Kris-Etherton, P.; Eckel, R.H.; Howard, B.V.; St Jeor, S.; Bazzarre, T.L.; Nutrition Committee \nPopulation Science Committee and Clinical Science Committee of the American Heart \nAssociation. AHA Science Advisory: Lyon diet h eart study.", "start_char_idx": 0, "end_char_idx": 2900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e085de5d-e30a-4739-ade6-6bb8d0f177e4": {"__data__": {"id_": "e085de5d-e30a-4739-ade6-6bb8d0f177e4", "embedding": null, "metadata": {"page_label": "28", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "14061b51-3fd6-463c-9b1d-53a4e0bf6fb4", "node_type": "4", "metadata": {"page_label": "28", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "cc180752e12c25a721cb47886e7d8b042beb551bd43c39c28f3550a91a68c3f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a23d123d-75c1-4a8e-b33c-d5398a638145", "node_type": "1", "metadata": {"page_label": "28", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "0ead5cdefef74af61418615f307a698042d40b1ac18c373c37d520ce3e439cc1", "class_name": "RelatedNodeInfo"}}, "text": "Weight loss with a low-carbohydrate,  mediterranean, or low-fat diet. \nN. Engl. J. Med. 2008 , 359, 229\u2013241. \n9. Trichopoulou, A.; Lagiou, P. Health y traditional Mediterranean di et: An expression of culture, \nhistory, and lifestyle. Nutr. Rev . 1997 , 55, 383\u2013389. \n10. Kris-Etherton, P.; Eckel, R.H.; Howard, B.V.; St Jeor, S.; Bazzarre, T.L.; Nutrition Committee \nPopulation Science Committee and Clinical Science Committee of the American Heart \nAssociation. AHA Science Advisory: Lyon diet h eart study. Benefits of a mediterranean-style, \nnational cholesterol education program/american  heart association step  I dietary pattern on \ncardiovascular disease. Circulation  2001 , 103, 1823\u20131825. \n11. Sofi, F.; Abbate, R.; Gensini, G.F.; Casini, A. Accruing evidence on benefits  of adherence to the \nMediterranean diet on health: An updated systematic review and meta-analysis. Am. J. Clin. Nutr . \n2010 , 92, 1189\u20131196.", "start_char_idx": 2391, "end_char_idx": 3317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d542be2-6f5d-448b-82a6-e3e10732d220": {"__data__": {"id_": "5d542be2-6f5d-448b-82a6-e3e10732d220", "embedding": null, "metadata": {"page_label": "29", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eaa8a52f-a714-4d3e-a134-1c2cc2e39422", "node_type": "4", "metadata": {"page_label": "29", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "ba0d99a3293ca1ad549161c8dd94e7a3896434962581c0433e5f4b1b29f69222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fff735ed-980d-4e5e-99ef-af941774cdd2", "node_type": "1", "metadata": {}, "hash": "4349325cae92c9008663bf8b73fc77a3e5f3dde29dec7df0e08fd54f122a7530", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3674 \n \n12. Estruchm, R.; Rosm, E.; Salas-Salvad\u00f3, J.; Covas,  M.I.; Corella, D.; Ar\u00f3s, F.; G\u00f3mez-Gracia, E.; \nRuiz-Guti\u00e9rrez, V.; Fiol, M.; Lapetra, J.; et al. Primary revention of cardiovascular disease with a \nMediterranean diet.  N. Engl. J. Med . 2013 , 368, 1279\u20131290. \n13. Appel, L.J.; Moore, T.J.; Obarzanek, E.; Vollmer, W.M.; Svetkey, L.P.; Saeks, F.M.; Bray, G.A.; \nVogt, T.M.; Cutler, J.A.; Windhauser, M.M.; et al . The effect of dietary patterns on blood \npressure: Results from the Dietary A pproaches to Stop Hypertension trial. N. Engl. J. Med . 1997 , \n336, 1117\u20131124. \n14. Sacks, F.M.; Obarzanek, E.; Windhauser, M.M. ; Svetkey, L.P.; Vollmer, W.M.; McCullough, M.; \nKaranja, N.; Lin, P.H.; St eele, P.; Proschan, M.A.; et al . Rationale and design of the Dietary \nApproaches to Stop Hypertension trial (DASH): A multicenter controlled fe eding study of dietary \npatterns to lower blood pressure. Ann. Epidemiol . 1995 , 5, 108\u2013118. \n15. Appel, L.J.; Champagne, C.M.; Harsha, D.W.; Cooper, L.S.; Obarzanek, E.; Elmer, P.J.;  \nStevens, V.J.; Vollmer, W.M.; Lin, P.H.; Svetkey, L.P.; et al.  Effects of comprehensive lifestyle \nmodification on blood pressure control: Main results of the premier clinical trial. JAMA  2003 , 289, \n2083\u20132093. \n16. Sacks, F.M.; Svetkey, L.P.; Vollmer, W.M.; Appel,  L.J.; Bray, G.A.; Harsha, D.; Obarzanek, E.; \nConlin, P.R.; Miller, E.R., III; Simons-Morton, D.G.; et al.  Effects on blood pressure of reduced \ndietary sodium and the Dietary Approach es to Stop Hypertension (DASH) diet.  N. Engl. J. Med . \n2001 , 344, 3\u201310. \n17. Blumenthal, J.A.; Babyak, M.A.; Hinderliter, A.; Watkins, L.L.; Craighead, L.; Lin, P.H.; Caccia, C.; \nJohnson, J.; Waugh, R.; Sherwood, A. Effects of th e DASH diet alone and in combination with \nexercise and weight loss on blood pr essure and cardiovascular biom arkers in men and women with \nhigh blood pressure: The ENCORE study. Arch. Intern. Med . 2010 , 170, 126\u2013135. \n18. Maruthur, N.M.; Wang N.Y.; Appel, L.J. Lifestyl e interventions reduce co ronary heart disease \nrisk: Results from the PREMIER trial. Circulation  2009 , 119, 2026\u20132031. \n19. Shai, I.; Spence, J.D.; Schw arzfuchs, D.; Henkin, Y.; Parraga, G.; Rudich, A.; Fenster,  A.; Mallett, C.; \nLiel-Cohen, N.; Tirosh, A.; et al . Dietary intervention to reve rse carotid atherosclerosis. \nCirculation  2010 , 121, 1200\u20131208. \n20. De Moura, F.F.; Lewis, K.D.; Falk, M.C. Appl ying the FDA definition of whole grains to the \nevidence for cardiovascular disease health claims. J. Nutr.  2009 , 139, 2220S\u20132226S.", "start_char_idx": 0, "end_char_idx": 2577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fff735ed-980d-4e5e-99ef-af941774cdd2": {"__data__": {"id_": "fff735ed-980d-4e5e-99ef-af941774cdd2", "embedding": null, "metadata": {"page_label": "29", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eaa8a52f-a714-4d3e-a134-1c2cc2e39422", "node_type": "4", "metadata": {"page_label": "29", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "ba0d99a3293ca1ad549161c8dd94e7a3896434962581c0433e5f4b1b29f69222", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d542be2-6f5d-448b-82a6-e3e10732d220", "node_type": "1", "metadata": {"page_label": "29", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "760cfa15039a782e30b0aa7f5b0415c29e6c7df4779237808054ec2bebba35e4", "class_name": "RelatedNodeInfo"}}, "text": "Circulation  2009 , 119, 2026\u20132031. \n19. Shai, I.; Spence, J.D.; Schw arzfuchs, D.; Henkin, Y.; Parraga, G.; Rudich, A.; Fenster,  A.; Mallett, C.; \nLiel-Cohen, N.; Tirosh, A.; et al . Dietary intervention to reve rse carotid atherosclerosis. \nCirculation  2010 , 121, 1200\u20131208. \n20. De Moura, F.F.; Lewis, K.D.; Falk, M.C. Appl ying the FDA definition of whole grains to the \nevidence for cardiovascular disease health claims. J. Nutr.  2009 , 139, 2220S\u20132226S. \n21. Prosky, L. When is dietary fiber considered a functional food? Biofactors 2000 , 12, 289\u2013297. \n22. Slavin, J.L. Position of the American Dietetic Association: Health implications of dietary fiber.  \nJ. Am. Diet. Assoc . 2008 , 108, 1716\u20131731. \n23. Kelly, S.A.; Summerbell, C.D.; Brynes, A.; Whitt aker, V.; Frost, G. Wholegrain cereals for \ncoronary heart disease. Cochrane Database Syst. Rev . 2007 , 18, CD005051. \n24. Brown, L.; Rosner, B.; Willett, W.W.; Sacks, F.M. C holesterol-lowering effects of dietary fiber: A \nmeta-analysis. Am. J. Clin. Nutr . 1999 , 69, 30\u201342. \n25. Marlett, J.A.; McBurney, M.I.; Slavin, J.L.; Am erican Dietetic Association. Position of the \nAmerican Dietetic Association: Hea lth implications of dietary fiber. J. Am. Diet. Assoc.  2002 , \n102, 993\u20131000.", "start_char_idx": 2114, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13a862ea-68ca-4d49-8bd2-cdc6ef44f8b7": {"__data__": {"id_": "13a862ea-68ca-4d49-8bd2-cdc6ef44f8b7", "embedding": null, "metadata": {"page_label": "30", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7b80ed4a-affa-4944-9bea-8d3cba483d10", "node_type": "4", "metadata": {"page_label": "30", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "b72141b69eff4ad30bf47bf1d733e493035c586df4b68aa1fb53dd9a97cfb716", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd01ca2e-63ac-4ad3-bd77-8b252be795be", "node_type": "1", "metadata": {}, "hash": "f6386162e08c9c676fe7e98492a4658b148fe98fc7248cd9d16041acfc31d1e3", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3675 \n \n26. Expert Panel on Detection, Evaluation, and Treat ment of High Blood Cholesterol in Adults. \nExecutive Summary of the Third Report of the Na tional Cholesterol Education Program (NCEP) \nExpert Panel on Detection, Evaluation, and Treatment  of High Blood Cholesterol in Adults (Adult \nTreatment Panel III). JAMA  2001 , 285, 2486\u20132497. \n27. Food and Drug Administration, HHS. Food labeling: Health claims; soluble fiber from certain \nfoods and risk of coronary hear t disease. Interim final rule. Fed. Regist.  2008 , 25, 9938\u20139947. \n28. Pennington, J.A.T.; Fisher, R.A. Classi fication of fruits and vegetables. J. Food. Compos. Anal. \n2009 , 22, S23\u2013S31. \n29. Dauchet, L.; Amouyel, P.; Hercberg, S.; Dallongevi lle, J. Fruit and vegetable consumption and \nrisk of coronary heart disease: A meta-analysis of cohort studies. J. Nutr . 2006 , 136, 2588\u20132593. \n30. Van Horn, L.; McCoin, M.; Kris-Etherton, P.M. ; Burke, F.; Carson, J.A.; Champagne, C.M.; \nKarmally, W.; Sikand, G. The evidence for dietar y prevention and treatment of cardiovascular \ndisease. J. Am. Diet. Assoc.  2008 , 108, 287\u2013331. \n31. Brufau, G.; Boatella, J.; Rafecas, M. Nu ts, source of energy and macronutrients.  Br. J. Nutr . 2006 , \n96, S24\u2013S28. \n32. Ros, E.; Mataix, J. Fa tty acid composition of nuts\u2014Impli cations for cardiovascular health. Br. J. Nutr . \n2006 , 96, S29\u2013S35. \n33. Emilio, R. Health Benefits of Nut Consumption. Nutrients  2010 , 2, 652\u2013682. \n34. Sabat\u00e9, J.; Ang, Y. Nuts and health outcomes: New epidemiologic evidence. Am. J. Clin. Nutr . \n2009 , 89, 1643S\u20131648S. \n35. Kris-Etherton, P.M.; Hu, F.B.; Ros, E.; Sabat\u00e9, J. The role of tree nut s and peanuts in the \nprevention of coronary heart diseas e: Multiple potential mechanisms. J. Nutr.  2008 , 138, \n1746S\u20131751S. \n36. Sabat\u00e9, J.; Oda, K.; Ros, E. Nut consumption and blood lipid levels: A pooled analysis of  \n25 intervention trials. Arch. Intern. Med . 2010 , 170, 821\u2013827. \n37. Kristen, S.; Montgomery, J. Soy protein. Perinat. Educ . 2003 , 12, 42\u201345. \n38. Pitkin, J. Alternative and compleme ntary therapies for the menopause. Menopause Int.  2012 , 18, \n20\u201327. \n39. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; Le Cornu, K.A.; Ryder, J.J.;  \nHall, W.L.; Cassidy, A. Flavonoids, flavonoid- rich foods, and cardiovascular risk: A \nmeta-analysis of randomized controlled trials. Am. J. Clin. Nutr . 2008 , 88, 38\u201350. \n40. Food labeling: Health claims; soy protein a nd coronary heart disease. Food and Drug \nAdministration, HHS, Final rule. Fed. Regist. 1999 , 64, 57700\u201357733. \n41. Micha, R.; Wallace, S.K.; Mozaffarian, D. Red and processed meat consumption and risk of \nincident coronary heart disease, stroke, and diabetes mellitus: A systematic review and \nmeta-analysis. Circulation  2010 , 121, 2271\u20132283.", "start_char_idx": 0, "end_char_idx": 2813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd01ca2e-63ac-4ad3-bd77-8b252be795be": {"__data__": {"id_": "fd01ca2e-63ac-4ad3-bd77-8b252be795be", "embedding": null, "metadata": {"page_label": "30", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7b80ed4a-affa-4944-9bea-8d3cba483d10", "node_type": "4", "metadata": {"page_label": "30", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "b72141b69eff4ad30bf47bf1d733e493035c586df4b68aa1fb53dd9a97cfb716", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13a862ea-68ca-4d49-8bd2-cdc6ef44f8b7", "node_type": "1", "metadata": {"page_label": "30", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "20531f9a6803a9fb4262796745b2b8789ecf7d415c8d23c75c56bd395a2c70b3", "class_name": "RelatedNodeInfo"}}, "text": "; Ryder, J.J.;  \nHall, W.L.; Cassidy, A. Flavonoids, flavonoid- rich foods, and cardiovascular risk: A \nmeta-analysis of randomized controlled trials. Am. J. Clin. Nutr . 2008 , 88, 38\u201350. \n40. Food labeling: Health claims; soy protein a nd coronary heart disease. Food and Drug \nAdministration, HHS, Final rule. Fed. Regist. 1999 , 64, 57700\u201357733. \n41. Micha, R.; Wallace, S.K.; Mozaffarian, D. Red and processed meat consumption and risk of \nincident coronary heart disease, stroke, and diabetes mellitus: A systematic review and \nmeta-analysis. Circulation  2010 , 121, 2271\u20132283. \n42. Dong, J.Y.; Qin, L.Q. Soy isoflavones consumpti on and risk of breast cancer incidence or \nrecurrence: A meta-analysis of prospective studies. Breast Cancer Res. Treat . 2011 , 125, 315\u2013323. \n43. Jakobsen, M.U.; O\u2019Reilly, E.J.; Heitmann, B.L.; Pereira, M.A.; B\u00e4lter, K.; Fraser, G.E.; \nGoldbourt, U.; Hallmans, G.; Knekt, P.; Liu, S.; et al . Major types of diet ary fat and risk of \ncoronary heart disease: A pooled analysis of 11 cohort studies. Am. J. Clin. Nutr.  2009 , 89, \n1425\u20131432.", "start_char_idx": 2229, "end_char_idx": 3309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf2922c-9507-4f0d-a216-3fdd02f1b18b": {"__data__": {"id_": "5bf2922c-9507-4f0d-a216-3fdd02f1b18b", "embedding": null, "metadata": {"page_label": "31", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9591e85f-fd5b-462c-8b35-c4874f654bde", "node_type": "4", "metadata": {"page_label": "31", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "a3076bc9206f5a705dcde88f37dbe6af590984f55f76c896ce1e5d323920babd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d627cb46-b3e3-4775-972d-33c028defa61", "node_type": "1", "metadata": {}, "hash": "b407e029ffe00bc3b014959f0ed47b51594aa96d85e3a552bf6df57a2dffc7ca", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3676 \n \n44. Elwood, P.C.; Pickering, J.E.; Givens, D.I.; Gall acher, J.E. The consumption of milk and  \ndairy foods and the incidence of vascular diseas e and diabetes: An overview of the evidence.  \nLipids  2010 , 45, 925\u2013939. \n45. Soedamah-Muthu, S.S.; Ding, E.L.; Al-Delaimy, W. K.; Hu, F.B.; Engberink, M.F.; Willett, W.C.; \nGeleijnse, J.M. Milk and dairy consumption and in cidence of cardiovascular diseases and all-cause \nmortality: Dose-response meta-analysi s of prospective cohort studies . Am. J. Clin. Nutr.  2011 , 93, \n158\u2013171. \n46. Eilat-Adar, S.; Xu, J.; Loria, C. ; Mattil, C.; Goldbourt, U.; Howar d, B.V.; Resnick, H.E. Dietary \ncalcium is associated with body mass i ndex and body fat in American Indians. J. Nutr . 2007 , 137, \n1955\u20131960. \n47. Tholstrup, T. Dairy products and cardiovascular disease. Curr. Opin. Lipidol . 2006 , 17, 1\u201310. \n48. German, J.B.; Gibson, R.A.; Krauss, R.M.; Nest el, P.; Lamarche, B.; van Staveren, W.A.;  \nSteijns, J.M.; de Groot, L.C.; Loc k, A.L.; Destaillats, F. A reappraisa l of the impact of dairy foods \nand milk fat on cardiovascular disease risk. Eur. J. Nutr . 2009 , 48, 191\u2013203. \n49. Hu, F.B.; Stampfer, M.J.; Manson, J.E.; Ascherio, A.; Colditz, G.A.; Speizer , F.E.; Hennekens, C.H.; \nWillett, W.C. Dietary saturated fats and their food s ources in relation to the risk of coronary heart \ndisease in women. Am. J. Clin. Nutr.  1999 , 70, 1001\u20131008. \n50. Marmoy, M.; Brunner, E. Alcohol and cardiovascular disease: The status of  the U-shaped curve. \nBMJ  1991 , 303, 565\u2013568. \n51. Ronksley, P.E.; Brien, S.E.; Turner, B.J.; Mukamal,  K.J.; Ghali, W.A. Association of alcohol \nconsumption with selected cardiovascular disease outcomes: A systematic review and \nmeta-analysis. BMJ 2011 , 342, d671. \n52. Goldberg, I.J.; Mosca, L.; Piano, M.R.; Fisher, E.A.; Nutrition Committee; Council on \nEpidemiology and Prevention; Council on Cardi ovascular Nursing of the American Heart \nAssociation. AHA Science Advisory: Wine and your  heart: A science advisory for healthcare \nprofessionals from the Nutrition Committee, Council on Epidemiology and Prevention, and \nCouncil on Cardiovascular Nursing of the American Heart Association. Circulation  2001 , 103, \n472\u2013475. \n53. Marmot, M.G. Alcohol and coronary heart disease. Int. J. Epidemiol.  2001 , 30, 724\u2013729. \n54. Mukamal, K.L.; Maclure, M.; Muller, J.E.; Mit tleman, M.A. Binge drinking and mortality after \nacute myocardial infarction. Circulation 2005 , 112, 3839\u20133845. \n55. Costanzo, S.; di Castelnuovo, A.; Donati, M.B.; Lac oviello, L.; de Gaetano, G. Cardiovascular and \noverall mortality risk in relation to alcohol cons umption in patients with cardiovascular disease. \nCirculation  2010 , 4, 1951\u20131959. \n56.", "start_char_idx": 0, "end_char_idx": 2747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d627cb46-b3e3-4775-972d-33c028defa61": {"__data__": {"id_": "d627cb46-b3e3-4775-972d-33c028defa61", "embedding": null, "metadata": {"page_label": "31", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9591e85f-fd5b-462c-8b35-c4874f654bde", "node_type": "4", "metadata": {"page_label": "31", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "a3076bc9206f5a705dcde88f37dbe6af590984f55f76c896ce1e5d323920babd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf2922c-9507-4f0d-a216-3fdd02f1b18b", "node_type": "1", "metadata": {"page_label": "31", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "a2125a73920be97ea990357e87c5b1a4e67ab902b7ba3dfdc15f001997de38ec", "class_name": "RelatedNodeInfo"}}, "text": "53. Marmot, M.G. Alcohol and coronary heart disease. Int. J. Epidemiol.  2001 , 30, 724\u2013729. \n54. Mukamal, K.L.; Maclure, M.; Muller, J.E.; Mit tleman, M.A. Binge drinking and mortality after \nacute myocardial infarction. Circulation 2005 , 112, 3839\u20133845. \n55. Costanzo, S.; di Castelnuovo, A.; Donati, M.B.; Lac oviello, L.; de Gaetano, G. Cardiovascular and \noverall mortality risk in relation to alcohol cons umption in patients with cardiovascular disease. \nCirculation  2010 , 4, 1951\u20131959. \n56. Corrao, G.; RubbiatI, L.; Bagnardi, V.; Zambon, A. ; Poikolainen, K. Alcohol and coronary heart \ndisease: A meta-analysis. Addiction  2000 , 95, 1505\u20131523. \n57. Corrao, G.; Bagnardi, V.; Zambon, A.; La Vecchia , C. A meta-analysis of alcohol consumption \nand the risk of 15 diseases. Prev. Med.  2004 , 38, 613\u2013619. \n58. Brien, S.E.; Ronksley, P.E.; Turner, B.J.; Mukama l, K.J.; Ghali, W.A. Effect of alcohol \nconsumption on biological markers associated with risk of corona ry heart disease: Systematic \nreview and meta-analysis of  interventional studies. BMJ  2011 , 342, d636.", "start_char_idx": 2246, "end_char_idx": 3329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be28483e-f94b-4a92-8061-d2d85e44b838": {"__data__": {"id_": "be28483e-f94b-4a92-8061-d2d85e44b838", "embedding": null, "metadata": {"page_label": "32", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "89305721-b50d-458c-b539-8f3b5feed0bd", "node_type": "4", "metadata": {"page_label": "32", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "c43c5809f6a0f767c7920f8692ae77f9db0e93afe337208f87331242b0b51980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d8c799-fac4-4de5-bb8d-b19d86b6805a", "node_type": "1", "metadata": {}, "hash": "c7bec740e976e73a2a0f847794448ea99818b4e45074cd1c456392e251c3cdb3", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3677 \n \n59. Kloner, R.A.; Rezkalla, S.H. To drink or  not to drink? That is the question. Circulation  2007 , 116, \n1306\u20131317. \n60. Seitz, H.K.; Pelucchi, C.; Bagnardi, V.; La Ve cchia, C. Epidemiology and pathophysiology of \nalcohol and breast cancer: Update 2012. Alcohol Alcohol.  2012 , 47, 204\u2013212. \n61. USDA National Nutrient Database for St andard Reference. Available online: \nhttp://www.nal.usda.gov/fnic/foodcomp/ search/ (accessed on 7 September 2012). \n62. Cornelis, M.C.; El-Sohemy, A. Coffee, caffeine, and coronary heart disease. Curr. Opin. Lipidol.  \n2007 , 18, 13\u201319. \n63. LaCroix, A.Z.; Mead, L.A.; Liang, K.Y.; Thomas , C.B.; Pearson, T.A. Coffee consumption and \nthe incidence of coronary heart disease. N. Engl. J. Med.  1986 , 16, 977\u2013982. \n64. Jick, H.; Miettinen, O.S.; Neff, R.K.; Shap iro, S.; Heinonen, O.P.; Slone, D. Coffee and \nmyocardial infarction.  N. Engl. J. Med . 1973 , 289, 63\u201367. \n65. Silletta, M.G.; Marfisi, R.; Levantesi, G.; Boccan elli, A.; Chieffo, C.; Franzosi, M.; Geraci, E.; \nMaggioni, A.P.; Nicolosi, G.; Schweiger, C.; et al. Coffee consumption and risk of cardiovascular \nevents after acute myocardial in farction: Results from the GISSI  (Gruppo Italiano per lo Studio \ndella Sopravvivenza nell\u2019Infarto miocardico)-Prevenzione trial. Circulation  2007 , 116, \n2944\u20132951. \n66. Mesas, A.E.; Leon-Mu\u00f1oz, L.M.; Rodriguez-Artalej o, F.; Lopez-Garcia, E. The effect of coffee on \nblood pressure and cardiovascular disease in hypertensive indivi duals: A systematic review and \nmeta-analysis. Am. J. Clin. Nutr.  2011 , 94, 1113\u20131126. \n67. Di Castelnuovo, A.; di Giuseppe, R.; Iacoviello, L. ; de Gaetano, G. Consumption of cocoa, tea and \ncoffee and risk of cardiovascular disease. Eur. J. Intern. Med.  2012 , 23, 15\u201325. \n68. De Koning Gans, J.M.; Uiterwaal, C.S.; van der Schouw, Y.T.; Boer, J.M.; Grobbee, D.E.; \nVerschuren, W.M.; Beulens, J.W. Tea and coffee consumption and cardiovascular morbidity and \nmortality. Arterioscler. Thromb. Vasc. Biol. 2010 , 30, 1665\u20131671. \n69. Sugiyama, K.; Kuriyama, S.; Akhter, M.; Kaki zaki, M.; Nakaya, N.; Ohmori-Matsuda, K.; \nShimazu, T.; Nagai, M.; Sugawara, Y.; Hozawa, A.; et al. Coffee consumption and mortality due \nto all causes, cardiovascular dise ase, and cancer in  Japanese women. J. Nutr . 2010 , 140, 1007\u20131013. \n70. Muley, A.; Muley, P.; Shah, M. Coffee to reduce ri sk of type 2 diabetes? A systematic review. \nCurr. Diabetes Rev.  2012 , 8, 162\u2013168. \n71. Higdon, J.V.; Frei, B. Coffee and health: A review of recent human research.", "start_char_idx": 0, "end_char_idx": 2557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d8c799-fac4-4de5-bb8d-b19d86b6805a": {"__data__": {"id_": "82d8c799-fac4-4de5-bb8d-b19d86b6805a", "embedding": null, "metadata": {"page_label": "32", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "89305721-b50d-458c-b539-8f3b5feed0bd", "node_type": "4", "metadata": {"page_label": "32", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "c43c5809f6a0f767c7920f8692ae77f9db0e93afe337208f87331242b0b51980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be28483e-f94b-4a92-8061-d2d85e44b838", "node_type": "1", "metadata": {"page_label": "32", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "cda23a00008d695c49e8174ea9097edb1c110195ecb6f22d62d69aa519f89497", "class_name": "RelatedNodeInfo"}}, "text": "69. Sugiyama, K.; Kuriyama, S.; Akhter, M.; Kaki zaki, M.; Nakaya, N.; Ohmori-Matsuda, K.; \nShimazu, T.; Nagai, M.; Sugawara, Y.; Hozawa, A.; et al. Coffee consumption and mortality due \nto all causes, cardiovascular dise ase, and cancer in  Japanese women. J. Nutr . 2010 , 140, 1007\u20131013. \n70. Muley, A.; Muley, P.; Shah, M. Coffee to reduce ri sk of type 2 diabetes? A systematic review. \nCurr. Diabetes Rev.  2012 , 8, 162\u2013168. \n71. Higdon, J.V.; Frei, B. Coffee and health: A review of recent human research. Crit. Rev. Food  \nSci. Nutr . 2006 , 46, 101\u2013123. \n72. Khan, N.; Mukhtar, H. Tea polyphenols for health promotion. Life Sci. 2007 , 81, 519\u2013533. \n73. Clement, Y. Can green tea do that? A litera ture review of the clinical evidence. Prev. Med. 2009 , \n49, 83\u201387. \n74. Kuriyama, S. The relation between green tea consumption and cardiovascular disease as evidenced \nby epidemiological studies. J. Nutr . 2008 , 138, 1548S\u20131553S. \n75. Wang, Z.M.; Zhou, B.; Wang, Y.S.; Gong, Q.Y.; Wang, Q.M.; Yan, J.J.; Gao, W.; Wang, L.S. \nBlack and green tea consumption and the risk of coronary artery disease: A meta-analysis.  \nAm. J. Clin. Nutr.  2011 , 93, 506\u2013515. \n76. Arab, L.; Liu, W.; Elashoff, D. Green and bl ack tea consumption and risk of stroke: A \nmeta-analysis. Stroke  2009 , 40, 1786\u20131792.", "start_char_idx": 2044, "end_char_idx": 3349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd1039e8-478d-4bec-a205-27df6fe0de3d": {"__data__": {"id_": "bd1039e8-478d-4bec-a205-27df6fe0de3d", "embedding": null, "metadata": {"page_label": "33", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56bf0e33-4e80-4fac-9b8f-1a418d45563e", "node_type": "4", "metadata": {"page_label": "33", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "37e067768124237b48b00702c96b3abf4a34746686eb21704e891f36059979e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbbd5846-5753-4572-942e-3b31727de57d", "node_type": "1", "metadata": {}, "hash": "c68445ac988ddcca5567a3eca300fa62373f805545d144ca7cf17af97836f97c", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3678 \n \n77. Deka, A.; Vita, J.A. Tea and cardiovascular disease. Pharmacol. Res.  2011 , 64, 36\u2013145. \n78. Brown, M.D. Green tea ( Camellia sinensis ) extract and its possible ro le in the prevention of \ncancer. Altern. Med. Rev.  1999 , 4, 360\u2013370. \n79. Sch\u00f6nthal, A.H. Adverse effects of concentrated green tea extracts. Mol. Nutr. Food. Res.  2011 , \n55, 874\u2013885. \n80. Cooper, K.A.; Donovan, J.L.; Waterhouse, A.L.; Williamson, G. Cocoa and health: A decade of \nresearch. Br. J. Nutr. 2008 , 99, 1\u201311. \n81. Ding, E.L.; Hutfless, S.M.; Ding, X.; Girotra, S.  Chocolate and prevention of cardiovascular \ndisease: A systematic review. Nutr. Metab. (Lond.)  2006 , 3, doi:10.1186/1743-7075-3-2. \n82. Buitrago-Lopez, A.; Sanderson, J.; Johnson, L.; Wa rnakula, S.; Wood, A.; di Angelantonio, E.; \nFranco, O.H. Chocolate consumption and cardiom etabolic disorders: Systematic review and \nmeta-analysis. BMJ  2011 , 343, d4488. \n83. Messerli, F.H. Chocolate consumption, cognitive function, and nobel laureates. N. Engl. J. Med.  \n2012 , 367, 1562\u20131564. \n84. Fern\u00e1ndez-Murga, L.; Tar\u00edn, J.J.; Garc\u00eda-Perez , M.A.; Cano, A. The impact of chocolate on \ncardiovascular health. Maturitas  2011 , 69, 312\u2013321. \n85. Rahman, K.; Lowe, G.M. Garlic and cardiovascular disease: A critical review.  J. Nutr.  2006 , 136, \n736S\u2013740S. \n86. Tattelman, E. Health effects of garlic. Am. Fam. Phys.  2005 , 7, 103\u2013106. \n87. Reinhart, K.M.; Talati, R.; White, C.M.; Coleman, C. I. The impact of garlic  on lipid parameters: A \nsystematic review and meta-analysis.  Nutr. Res. Rev. 2009 , 22, 39\u201348. \n88. Khoo, Y.S.; Aziz, Z. Garlic supplementation and serum cholesterol: A meta-analysis. J. Clin. \nPharm. Ther.  2009 , 34, 133\u2013145. \n89. Ackermann, R.T.; Mulrow, C.D.; Ramirez, G.; Gardner, C.D.; Morbidoni, L.; Lawrence, V.A. \nGarlic shows promise for improving so me cardiovascular risk factors. Arch. Intern. Med . 2001 , \n161, 813\u2013824. \n90. Kritchevsky, S.B.; Kritchevsky, D. Egg cons umption and coronary heart disease: An \nepidemiologic overview. J. Am. Coll. Nutr . 2000 , 19, 549S\u2013555S. \n91. Jones, P.J. Dietary cholesterol and the risk of ca rdiovascular disease in pa tients: A review of the \nHarvard Egg Study and other data. Int. J. Clin. Pract. Suppl . 2009 , 63, 28\u201336. \n92. USDA Food Tables. Available online: http:/ /ndb.nal.usda.gov/ndb/foods /show/111?fg=Dairy+ \nand+Egg+Products&man=&lfacet=&format=&c ount=&max=25&offset=100&sort=&qlookup= \n(accessed on 27 October 2012). \n93. Dawber, T.R.; Nickerson, R.J.; Brand, F.N.", "start_char_idx": 0, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbbd5846-5753-4572-942e-3b31727de57d": {"__data__": {"id_": "dbbd5846-5753-4572-942e-3b31727de57d", "embedding": null, "metadata": {"page_label": "33", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56bf0e33-4e80-4fac-9b8f-1a418d45563e", "node_type": "4", "metadata": {"page_label": "33", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "37e067768124237b48b00702c96b3abf4a34746686eb21704e891f36059979e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd1039e8-478d-4bec-a205-27df6fe0de3d", "node_type": "1", "metadata": {"page_label": "33", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "446e5d41adb6e9fb1192fc7acb92f1aa61ed0c4755cb148075660731f7de3b31", "class_name": "RelatedNodeInfo"}}, "text": "J. Am. Coll. Nutr . 2000 , 19, 549S\u2013555S. \n91. Jones, P.J. Dietary cholesterol and the risk of ca rdiovascular disease in pa tients: A review of the \nHarvard Egg Study and other data. Int. J. Clin. Pract. Suppl . 2009 , 63, 28\u201336. \n92. USDA Food Tables. Available online: http:/ /ndb.nal.usda.gov/ndb/foods /show/111?fg=Dairy+ \nand+Egg+Products&man=&lfacet=&format=&c ount=&max=25&offset=100&sort=&qlookup= \n(accessed on 27 October 2012). \n93. Dawber, T.R.; Nickerson, R.J.; Brand, F.N.; Pool, J.  Eggs, serum cholesterol, and coronary heart \ndisease. Am. J. Clin. Nutr.  1982 , 36, 617\u2013625. \n94. Qureshi, A.I.; Suri, F.K.; Ahmed, S.; Nasar, A.; Divani, A.A.; Kirmani, J.F. Regular egg \nconsumption does not increase the risk of  stroke and cardiovascular diseases. Med. Sci. Monit . \n2007 , 13, CR1\u2013CR8. \n95. Hu, F.B.; Stampfer, M.J.; Rimm, E.B.; Manson, J. E.; Ascherio, A.; Colditz, G.A.; Rosner, B.A.; \nSpiegelman, D.; Speizer, F.E.; Sacks, F.M.; et al. A prospective study of egg consumption and risk \nof cardiovascular disease in men and women. JAMA  1999 , 281, 1387\u20131394.", "start_char_idx": 2048, "end_char_idx": 3127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ad5525-4bea-4787-8b4b-7e48b21d4159": {"__data__": {"id_": "36ad5525-4bea-4787-8b4b-7e48b21d4159", "embedding": null, "metadata": {"page_label": "34", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e52504b3-5057-47b9-a518-b38c93c085d7", "node_type": "4", "metadata": {"page_label": "34", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "61327daa3fcbf3bf355b9e93b33c36b23e7c801559e6bc70fbed64dc63c2abc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07b742ad-2db3-4264-adeb-eedee52dcd91", "node_type": "1", "metadata": {}, "hash": "d902fae54c3efb788a8530ab7731a8f7f7152fd3cc795f9213900cd245fdd07d", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3679 \n \n96. Djouss\u00e9, L.; Gaziano, J.M. Egg consumption and risk  of heart failure in the Physicians\u2019 Health \nStudy. Circulation  2008 , 117, 512\u2013516. \n97. Djouss\u00e9, L.; Gaziano, J.M. Egg consumption in re lation to cardiovascular disease and mortality: \nThe Physicians\u2019 Health Study. Am. J. Clin. Nutr.  2008 , 87, 964\u2013969. \n98. Djouss\u00e9, L.; Gaziano, J.M.; Buring, J. E.; Lee, I.M. Egg consumption a nd risk of type 2 diabetes in \nmen and women.  Diabetes Care  2009 , 32, 295\u2013300. \n99. Weggemans, R.M.; Zock, P.L.; Katan, M.B. Diet ary cholesterol from eggs increases the  \nratio of total cholesterol to hi gh-density lipoprotein cholesterol in humans: A meta-analysis.  \nAm. J. Clin. Nutr . 2001 , 73, 885\u2013891. \n100. Glatz, J.F.; Turner, PR.; Katan, M.B.; Stalenho ef, A.F.; Lewis, B. Hypo- and hyperresponse of \nserum cholesterol level and low density lipoprotein production and degradation to dietary \ncholesterol in man. Ann. N. Y. Acad. Sci.  1993 , 676, 163\u2013179. \n101. He, F.J.; MacGregor, G.A. Effect of modest salt  reduction on blood pressure: A meta-analysis of \nrandomized trials: Implications for public health. J. Hum.  Hypertens . 2002 , 16, 761\u2013770. \n102. Taylor, R.S.; Ashton, K.E.; Moxham, T.; Hooper, L. ; Ebrahim, S. Reduced dietary salt for the \nprevention of cardiovascular disease. Cochrane Database Syst. Rev . 2011 , 7, CD009217. \n103. IOM Committee Report on Sodium Intake in Populations. Available online: \nhttp://www.iom.edu/Reports/2013/Sodium-Intake -in-Populations-Assessment-of-Evidence.aspx \n(accessed on 25 August 2013). \n104. Bjelakovic, G.; Nikolova, D.; Gluud, L.L.; Sim onetti, R.G.; Gluud, C. Antioxidant supplements \nfor prevention of mortality in  healthy participants and pa tients with various diseases. Cochrane \nDatabase Syst. Rev.  2012 , 3, CD007176. \n105. Honarbakhsh, S.; Schachter, M. Vitamins and cardiovascular disease . Br. J. Nutr.  2009 , 101, \n1113\u20131131. \n106. Sesso, H.D.; Christen, W.G.; Bubes, V.; Smith, J.P.; MacFadyen, J.; Schva rtz, M.; Manson, J.E.; \nGlynn, R.J.; Buring, J.E.; Gaziano, J.M. Multivitamin s in the prevention of cardiovascular disease \nin men: The Physicians\u2019 Health St udy II randomized controlled trial. JAMA  2012 , 708, 751\u2013760. \n107. Holick, M.F. Evidence-based D-bate on health benefits of Vitamin D revisited. \nDermato-endocrinology  2012 , 4, 83\u201390. \n108. Holick, M.D. Vitamin D deficiency. N. Engl. J. Med.  2007 , 357, 266\u2013281. \n109. Sokol, S.I.; Tsang, P.; Aggarwal, V.; Melamed, M.L.; Srinivas, V.S. Vitamin D status and risk of \ncardiovascular events: Lessons learned via systematic review and meta-analysis. Cardiol. Rev.  \n2011 , 19, 192\u2013201. \n110. Grandi, N.C.; Breitling, L.P.", "start_char_idx": 0, "end_char_idx": 2691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07b742ad-2db3-4264-adeb-eedee52dcd91": {"__data__": {"id_": "07b742ad-2db3-4264-adeb-eedee52dcd91", "embedding": null, "metadata": {"page_label": "34", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e52504b3-5057-47b9-a518-b38c93c085d7", "node_type": "4", "metadata": {"page_label": "34", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "61327daa3fcbf3bf355b9e93b33c36b23e7c801559e6bc70fbed64dc63c2abc8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ad5525-4bea-4787-8b4b-7e48b21d4159", "node_type": "1", "metadata": {"page_label": "34", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "90675aafa237f8863c297c3cdb9148409c891d49436bad470a87850258db167d", "class_name": "RelatedNodeInfo"}}, "text": "JAMA  2012 , 708, 751\u2013760. \n107. Holick, M.F. Evidence-based D-bate on health benefits of Vitamin D revisited. \nDermato-endocrinology  2012 , 4, 83\u201390. \n108. Holick, M.D. Vitamin D deficiency. N. Engl. J. Med.  2007 , 357, 266\u2013281. \n109. Sokol, S.I.; Tsang, P.; Aggarwal, V.; Melamed, M.L.; Srinivas, V.S. Vitamin D status and risk of \ncardiovascular events: Lessons learned via systematic review and meta-analysis. Cardiol. Rev.  \n2011 , 19, 192\u2013201. \n110. Grandi, N.C.; Breitling, L.P.; Brenner, H. V itamin D and cardiovascular disease: Systematic \nreview and meta-analysis of prospective studies.  Prev. Med.  2010 , 51, 228\u2013233. \n111. Wang, L.; Song, Y.; Manson, J.E.; Pilz, S.; M\u00e4 rz, W.; Micha\u00eblsson, K.; Lundqvist, A.;  \nJassal, S.K.; Barrett-Connor, E.; Zhang, C.; et al. Circulating 25-hydroxy-vitamin d and risk of \ncardiovascular disease: A meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes  \n2012 , 5, 819\u2013829. \n112. Pittas, A.G.; Chung, M.; Trikalinos, T.; Mitrim, J; Brendel, M.; Patel, K.; Lichtenstein, A.H.;  \nLau, J.; Balk, E.M. Systematic review: Vitamin D and cardio metabolic outcomes. Ann. Intern. Med . \n2010 , 152, 307\u2013314.", "start_char_idx": 2204, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67f8569b-d127-4360-81bc-6456452f0cf9": {"__data__": {"id_": "67f8569b-d127-4360-81bc-6456452f0cf9", "embedding": null, "metadata": {"page_label": "35", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b87b2a23-5be1-465a-8db3-ee1221937513", "node_type": "4", "metadata": {"page_label": "35", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "620726aff35184a0db115a74ae8b59a4d3331cab50b7768994bcb70ce179c774", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ddf7af6-435b-4257-9022-8363dfe93cd2", "node_type": "1", "metadata": {}, "hash": "e707aa1e1bd7ea8b6bc7d958ae7d128d0da77b4f5a7c02ddb16df382a4830fc1", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3680 \n \n113. Esposti, M.D.; Ngo, A.; Ghelli, A.; Benelli, B.; Carelli, V.; McLennan, H.; Linnane, A.W.  \nThe interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the \nrespiratory complexes of heart mitochondria. Arch. Biochem. Biophys.  1996 , 330, 395\u2013400. \n114. Ernster, L.; Dallner, G. Biochemical, physiologi cal and medical aspects of ubiquinone function. \nBiochim. Biophys. Acta  1995 , 1271 , 195\u2013204. \n115. McMurray, J.J.V.; Dunselman, P.; Wedel, H.; Cleland, J.G.F.; Lindberg, M.; Hjalmarson, A.;  \nKjekshus, J.; Waagstein, F.; Apetrei, E.; Barrios, V.; et al . Coenzyme Q10, rosuvastatin, and \nclinical outcomes in heart failure. J. Am. Coll. Cardiol . 2010 , 56, 1196\u20131204. \n116. Overvad, K.; Diamant, B.; Holm, L.; Holmer, G.; Mo rtensen, S.A.; Stender, S. Coenzyme Q10 in \nhealth and disease. Eur. J. Clin. Nutr . 1999 , 53, 764\u2013770. \n117. Sander, S.; Coleman, C.I.; Patel, A.A.; Kluger, J.; White, C.M. The impact of coenzyme Q10 on \nsystolic function in patients  with chronic heart failure. J. Card. Fail.  2006 , 12, 464\u2013472. \n118. Gao, L.; Mao, Q.; Cao, J.; Wang, Y.; Zhou, X.; Fan, L. Effects of coenzy me Q10 on vascular \nendothelial function in huma ns: A meta-analysis of ra ndomized controlled trials. Atherosclerosis  \n2012 , 221, 311\u2013316. \n119. Ho, M.J.; Bellusci, A.; Wright, J.M. Blood pre ssure lowering efficacy of coenzyme Q10 for \nprimary hypertension. Cochrane Database Syst. Rev . 2009 , 4, CD007435. \n120. Vandenberg, B.F.; Robinson, J. Management of  the patient with st atin intolerance. Curr. \nAtheroscler. Rep . 2010 , 12, 48\u201357. \n121. Bookstaver, D.A.; Burkhalter, N.A.; Hatzigeorgi ou, C. Effect of coenzyme Q10 supplementation \non statin-induced myalgias. Am. J. Cardiol . 2012 , 110, 526\u2013529. \n122. Supplements. National Institutes of Health. Available online: http ://ods.od.nih.gov/factsheets/ \nmagnesium.asp (accessed on 19 January 2010). \n123. Seelig, M.S.; Rosanoff, A. The Magnesium Factor ; Avery: New York, NY, USA, 2003. \n124. Liao, F.; Folsom, A.R.; Brancati, F.L. Is low magnesium concentra tion a risk factor for coronary \nheart disease? The Atherosclerosi s Risk in Communities (ARIC) study. Am. Heart J . 1998 , 136, \n480\u2013490. \n125. Schulze, M.B.; Schulz, M.; Heidemann, C.; Schi enkiewitz, A.; Hoffmann, K.; Boeing, H. Fiber \nand magnesium intake and incidence of type 2 diabetes. A prospective study and meta-analysis. \nArch. Intern. Med.  2007 , 167, 956\u2013965. \n126. Shechter, M. Magnesium and cardiovascular system. Magnes. Res.  2010 , 23, 1\u201313. \n127. He, K.; Liu, K.; Daviglus, M.L.; Loria, C.M.", "start_char_idx": 0, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ddf7af6-435b-4257-9022-8363dfe93cd2": {"__data__": {"id_": "8ddf7af6-435b-4257-9022-8363dfe93cd2", "embedding": null, "metadata": {"page_label": "35", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b87b2a23-5be1-465a-8db3-ee1221937513", "node_type": "4", "metadata": {"page_label": "35", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "620726aff35184a0db115a74ae8b59a4d3331cab50b7768994bcb70ce179c774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67f8569b-d127-4360-81bc-6456452f0cf9", "node_type": "1", "metadata": {"page_label": "35", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "fe35783be6d9c4883d6c1eaf8f63b9e88ba12cf6ebe7d13138b037a4cffd89d8", "class_name": "RelatedNodeInfo"}}, "text": "Is low magnesium concentra tion a risk factor for coronary \nheart disease? The Atherosclerosi s Risk in Communities (ARIC) study. Am. Heart J . 1998 , 136, \n480\u2013490. \n125. Schulze, M.B.; Schulz, M.; Heidemann, C.; Schi enkiewitz, A.; Hoffmann, K.; Boeing, H. Fiber \nand magnesium intake and incidence of type 2 diabetes. A prospective study and meta-analysis. \nArch. Intern. Med.  2007 , 167, 956\u2013965. \n126. Shechter, M. Magnesium and cardiovascular system. Magnes. Res.  2010 , 23, 1\u201313. \n127. He, K.; Liu, K.; Daviglus, M.L.; Loria, C.M.; Van Horn, L.; Jacobs, D.R., Jr.; Savage, P.J. \nMagnesium intake and incidence of  metabolic syndrome among young adults. Circulation  2006 , \n113, 1675\u20131682. \n128. Shechter, M. Magnesium and cardiovascular system. Magnes. Res.  2010 , 23, 60\u201372. \n129. Stepura, O.B.; Martynow, A.I. Magnesium orotat e in severe congestive heart failure (MACH).  \nInt. J. Cardiol.  2009 , 131, 293\u2013295. \n130. Shechter, M.; Sharir, M.; Labrador, M.; Forrest er, J.; Silver, B.; Bair ey Merz, C.N. Oral \nmagnesium therapy improves endothelial function in  patients with coronary artery disease. \nCirculation  2000 , 102, 2353\u20132358.", "start_char_idx": 2066, "end_char_idx": 3218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c03a8b-8f7a-4b65-918a-3716365e8529": {"__data__": {"id_": "c5c03a8b-8f7a-4b65-918a-3716365e8529", "embedding": null, "metadata": {"page_label": "36", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4b30fa72-0d96-4d4c-8501-338f0fbff9c5", "node_type": "4", "metadata": {"page_label": "36", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "a49d0303fae6e6c378fdcdaead002fc032016cd210582fa5959e0746857649ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c4fa3c0-3c38-4ff1-9d1d-f37950055f36", "node_type": "1", "metadata": {}, "hash": "490033ba21ad815fa456ada145f220043d4dac9bac3c3f2e694a47f46d468eef", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3681 \n \n131. Shechter, M.; Bairey Merz, C.N.; Paul-Labrado r, M.; Meisel, S.R.; Rude, R.K.; Molloy, M.D.; \nDwyer, J.H.; Shah, P.K.; Kaul, S. Oral magnesium  supplementation inhibits platelet-dependent \nthrombosis in patients with coronary artery disease. Am. J. Cardiol.  1999 , 84, 152\u2013156. \n132. Kark, J.D.; Selhub, J.; Adler, B.; Gofin, J.; Abramson, J.H.; Friedman, G.; Rosenberg, I.H. \nNonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and \nwomen in jerusalem. Ann. Intern. Med.  1999 , 131, 321\u2013330. \n133. Wolff, T.; Witkop, C.T.; Miller, T.; Syed, S.B. Folic acid supplementation for the prevention of \nneural tube defects: An update of the evidence for the U.S. Preventive Services Task Force. Ann. \nIntern. Med.  2009 , 150, 632\u2013639. \n134. Eilat-Adar, S.; Goldbourt, U. Nutritional recomm endations for preventing coronary heart disease \nin women: Evidence concerning whole foods and supplements. Nutr. Metab. Cardiovasc. Dis.  \n2010 , doi:10.1016/j.numecd.2010.01.011. \n135. B\u00f8naa, K.H.; Nj\u00f8lstad, I.; Ueland, P.M.; Schirm er, H.; Tverdal, A.; Steigen, T.; Wang, H.;  \nNordrehaug, J.E.; Arnesen, E.; Rasmussen, K.; et al. Homocysteine Lowering and Cardiovascular \nEvents after Acute Myocardial Infarction. N. Engl. J. Med.  2006 , 354, 1578\u20131588. \n136. Lee, M.; Hong, K.S.; Chang, S.C.; Saver, J.L. E fficacy of homocysteine-l owering therapy with \nfolic acid in stroke prev ention: A meta-analysis. Stroke  2010 , 41, 1205\u20131212. \n137. Jardine, M.J.; Kang, A.; Zoungas,  S.; Navaneethan, S.D.; Ninomiya, T.; Nigwekar, S.U.; \nGallagher, M.P.; Cass, A.; Strippoli , G.; Perkovic, V. The effect of  folic acid based homocysteine \nlowering on cardiovascular events in people w ith kidney disease: Systematic review and \nmeta-analysis. BMJ  2012 , 344, e3533. \n138. Plourde, M.; Cunnane, S.C. Extremely limited synt hesis of long chain polyuns aturates in adults: \nImplications for their dietary esse ntiality and use as supplements. Appl. Physiol. Nutr. Metab.  \n2007 , 32, 619\u2013634. \n139. Neubronner, J.P.; Schuchardt, G.; Kressel, G.; Merkel, M.; von Schacky, C. ; Hahn, A.L. Enhanced \nincrease of omega-3 index in response to long-term n-3 fatty acid supplementation from \ntriacylglycerides versus ethyl esters . Eur. J. Clin. Nutr.  2011 , 65, 247\u2013254. \n140. Kris-Etherton, P.M.; Harris, W.S.; Appel, L.J. Fish  consumption, fish oil, omega-3 fatty acids, and \ncardiovascular disease. Circulation  2002 , 106, 2747\u20132757. \n141. Gr\u00f8nbaek, M. Fish consumption and coronary hear t disease mortality. A systematic review of \nprospective cohort studies.  Eur. J. Clin. Nutr.  1999 , 53, 585\u2013590. \n142.", "start_char_idx": 0, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c4fa3c0-3c38-4ff1-9d1d-f37950055f36": {"__data__": {"id_": "5c4fa3c0-3c38-4ff1-9d1d-f37950055f36", "embedding": null, "metadata": {"page_label": "36", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4b30fa72-0d96-4d4c-8501-338f0fbff9c5", "node_type": "4", "metadata": {"page_label": "36", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "a49d0303fae6e6c378fdcdaead002fc032016cd210582fa5959e0746857649ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c03a8b-8f7a-4b65-918a-3716365e8529", "node_type": "1", "metadata": {"page_label": "36", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "8f150babb113f971f0427991ff9c28116a3fd7adfa659cc8329cd824b2fc7cbf", "class_name": "RelatedNodeInfo"}}, "text": "Enhanced \nincrease of omega-3 index in response to long-term n-3 fatty acid supplementation from \ntriacylglycerides versus ethyl esters . Eur. J. Clin. Nutr.  2011 , 65, 247\u2013254. \n140. Kris-Etherton, P.M.; Harris, W.S.; Appel, L.J. Fish  consumption, fish oil, omega-3 fatty acids, and \ncardiovascular disease. Circulation  2002 , 106, 2747\u20132757. \n141. Gr\u00f8nbaek, M. Fish consumption and coronary hear t disease mortality. A systematic review of \nprospective cohort studies.  Eur. J. Clin. Nutr.  1999 , 53, 585\u2013590. \n142. Bucher, H.C.; Hengstler, P.; Schindler, C.; Meier, G. N-3 polyunsaturated fatty acids in coronary \nheart disease: A meta-analysis of  randomized controlled trials. Am. J. Med . 2002 , 112, 298\u2013304. \n143. Studer, M.; Briel, M.; Leimenstoll, B.; Glass, T.R. ; Bucher, H.C. Effect of  different antilipidemic \nagents and diets on mortality: A systematic review. Arch. Intern. Med . 2005 , 165, 725\u2013730. \n144. Rauch, B.; Schiele, R.; Schneider, S.; Diller , F.; Victor, N.; Gohlke, H.; Gottwik, M.;  \nSteinbeck, G.; del Castillo, U.; Sack, R.; et al. OMEGA, a randomized, plac ebo-controlled trial to \ntest the effect of highly purified Omega-3 Fatty Acids on top of modern guideline-adjusted therapy \nafter myocardial infarction. Circulation  2010 , 122, 2152\u20132159. \n145. Bosch, J.; Gerstein, H.C.; Dagenais, G.R.; D\u00edaz, R.; Dyal, L.; Jung, H.; Maggiono, A.P.; \nProbstfield, J.; Ramachandran, A.; Riddle, M.C. N-3 fatty acids and cardiovascular outcomes in \npatients with dysglycemia. N. Engl. J. Med . 2012 , 367, 309\u2013318.", "start_char_idx": 2140, "end_char_idx": 3682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4225d9ac-4cad-4a20-8a7e-21531a6d6063": {"__data__": {"id_": "4225d9ac-4cad-4a20-8a7e-21531a6d6063", "embedding": null, "metadata": {"page_label": "37", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "59bba3f0-274c-4ade-8538-fd0e28432ab1", "node_type": "4", "metadata": {"page_label": "37", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "d7775d2e01667bc21b2f47450c79c2d82fb7dce91a8f4e60c907789503967b96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec8d9b0-9048-4088-ba4f-b043fd710713", "node_type": "1", "metadata": {}, "hash": "8a2cf1e1ccaa36872425f8ef01c3b53c2e3ff75015f861016b2dc48097c2ecdd", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3682 \n \n146. Kromhout, D.; Giltay, E.J.; Geleijnse, J.M. N-3 fatty acids and cardiovascular events after \nmyocardial infarction. N. Engl. J. Med.  2010 , 363, 2015\u20132026. \n147. Galan, P.; Kesse-Guyot, E.; Czernichow, S.; Brianc on, S.; Blacher, J.; Hercberg, S. Effects of B \nVitamins and omega 3 fatty acids on cardiovas cular diseases: A randomized placebo controlled \ntrial. BMJ  2010 , 341, c6273. \n148. Kwak, S.M.; Myung, S.K.; Lee, Y.J.; Seo, H.G.; Korean Meta-analysis Study Group. Efficacy of \nOmega-3 fatty acid supplements (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the secondary prevention of cardiovascular disease:  A meta-analysis of ra ndomized, double-blind, \nplacebo-controlled trials. Arch. Intern. Med . 2012 , 172, 686\u2013694. \n149. Chowdhury, R.; Stevens, S.; Gorman, D.; Pan, A.; Warnakula, S.; Chowdhury, S.; Ward, H.; \nJohnson, L.; Crowe, F.; Hu, F.B.; et al . Association between fish consumption, long chain  \nomega 3 fatty acids, and risk of  cerebrovascular disease: System atic review and meta-analysis. \nBMJ  2012 , 345, e6698. \n150. Liu, T.; Korantzopoulos, P.; Shehata, M.; Li, G.; Wang, X.; Kaul, S. Prevention of atrial \nfibrillation with omega-3 fatty acids: A meta -analysis of randomised clinical trials. Heart  2011 , \n97, 1034\u20131040. \n151. Rizos, E.C.; Ntzani, E.E.; Bika, E.; Kostapanos, M.S.; Elisaf, M.S. Association between omega-3 \nfatty acid supplementation and risk of major cardi ovascular disease events: A systematic review \nand meta-analysis. JAMA  2012 , 308, 1024\u20131033. \n152. Kromhout, D.; Yasuda, S.; Geleijnse, J.M.; Shimoka wa, H. Fish oil and omega-3 fatty acids in \ncardiovascular disease: Do they really work? Eur. Heart J . 2012 , 33, 436\u2013443. \n153. Lau, J. Effects of omega-3 fatty acids on seru m markers of cardiovascular disease risk: A \nsystematic review. Atherosclerosis  2006 , 189, 19\u201330. \n154. Moreau, R.A.; Whitaker, B.D.; Hicks, K.B. Phyt osterols, phytostanols, and their conjugates in \nfoods: Structural diversity, quantitative  analysis, and health-promoting uses. Prog. Lipid Res.  \n2002 , 41, 457\u2013500. \n155. Talati, R.; Sobieraj, D.M.; Makanji, S.S.; Phung, O.J.; Coleman, C.I. The comparative efficacy of \nplant sterols and stanols on serum lipids: A systematic review and meta-analysis. J. Am. Diet. Assoc.  \n2010 , 110, 719\u2013726. \n156. Hansel, B.; Nicolle, C.; Lalanne, F.; Tondu, F. ; Lassel, T.; Donazzolo, Y.; Ferri\u00e8res, J.;  \nKrempf, M.; Schlienger, J.L.; Verges, B.; et al. Effect of low-fat, fermented milk enriched with \nplant sterols on serum lipid profile and oxida tive stress in moderate hypercholesterolemia. Am. J. \nClin. Nutr.  2007 , 86, 790\u2013796. \n157.", "start_char_idx": 0, "end_char_idx": 2667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec8d9b0-9048-4088-ba4f-b043fd710713": {"__data__": {"id_": "bec8d9b0-9048-4088-ba4f-b043fd710713", "embedding": null, "metadata": {"page_label": "37", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "59bba3f0-274c-4ade-8538-fd0e28432ab1", "node_type": "4", "metadata": {"page_label": "37", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "d7775d2e01667bc21b2f47450c79c2d82fb7dce91a8f4e60c907789503967b96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4225d9ac-4cad-4a20-8a7e-21531a6d6063", "node_type": "1", "metadata": {"page_label": "37", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "56cb22d14e37358edab96f933f49bb99b441a4bfa35d22305edafa9410eb68b5", "class_name": "RelatedNodeInfo"}}, "text": "; Makanji, S.S.; Phung, O.J.; Coleman, C.I. The comparative efficacy of \nplant sterols and stanols on serum lipids: A systematic review and meta-analysis. J. Am. Diet. Assoc.  \n2010 , 110, 719\u2013726. \n156. Hansel, B.; Nicolle, C.; Lalanne, F.; Tondu, F. ; Lassel, T.; Donazzolo, Y.; Ferri\u00e8res, J.;  \nKrempf, M.; Schlienger, J.L.; Verges, B.; et al. Effect of low-fat, fermented milk enriched with \nplant sterols on serum lipid profile and oxida tive stress in moderate hypercholesterolemia. Am. J. \nClin. Nutr.  2007 , 86, 790\u2013796. \n157. Homma, Y.; Ikeda, I.; Ishikawa, T.; Taterno, M.; Sugano, M.; Naka mura, H. Decrease in plasma \nlow-density lipoprotein cholestero l, apolipoprotein B, cholestery l ester transfer protein, and \noxidized low-density lipoprotein by plant sta nol ester-containing spread: A randomized, \nplacebo-controlled trial. Nutrition  2003 , 19, 369\u2013374. \n158. Nestel, P.; Cehun, M.; Pomeroy, S.; Abbey, M.; El don, G. Cholesterol-lowering effects of plant \nsterol esters and non-esteri fied stanols in margarine, butter and low-fat foods. Eur. J. Clin. Nutr.  \n2001 , 55, 1084\u20131090.", "start_char_idx": 2132, "end_char_idx": 3236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68983b9b-6c16-4a4d-a5a2-8d4ee617a21a": {"__data__": {"id_": "68983b9b-6c16-4a4d-a5a2-8d4ee617a21a", "embedding": null, "metadata": {"page_label": "38", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "437a834a-0cb4-4c5a-b986-2e608c16e623", "node_type": "4", "metadata": {"page_label": "38", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}, "hash": "30dc777aec08fa2dcf53d4249103035da251b9499b39d645cb66918863219bc2", "class_name": "RelatedNodeInfo"}}, "text": "Nutrients 2013 , 5 3683 \n \n159. Williams, C.L.; Bollella, M.C.; Strobino, B.A.; Boccia, L.; Campanaro, L. Plant stanol ester and \nbran fiber in childhood: E ffects on lipids, stool weight and stool  frequency in preschool children.  \nJ. Am. Coll. Nutr.  1999 , 18, 572\u2013581. \n160. Lee, Y.M.; Haastert, B.; Scherbaum, W.; Hauner,  H. A phytosterol-enriched spread improves the \nlipid profile of subjects with  type 2 diabetes mellitus\u2014A ra ndomized controlled trial under \nfree-living conditions. Eur. J. Nutr . 2003 , 42, 111\u2013117. \n161. Demonty, I.; Ras, R.T.; van der Knaap, H.C.M.; Du chateau, G.S.M.J.E.; Meijer, L.; Zock, P.L.;  \nGeleijnse, J.M.; Trautwein, E.A. Continuous dose-response relations hip of the LDL-Cholesterol\u2014 \nLowering effect of phytosterol intake. J. Nutr.  2009 , 139, 271\u2013284. \n162. Blair, S.N.; Capuzzi, D.M.; Got tlieb, S.O.; Nguyen, T.; Morgan, J. M.; Cater, N.M. Incremental \nreduction of serum total cholesterol and low-dens ity lipoprotein cholestero l with the addition of \nplant stanol ester-containing spread to statin therapy. Am. J. Cardiol . 2000 , 86, 46\u201352. \n163. Ntanios, F.Y.; Jones, P.J.H. Dietary sitostanol reciprocally influences cholesterol absorption and \nbiosynthesis in hamsters and rabbits . Atherosclerosis  1999 , 143, 341\u2013351. \n164. Hendriks, H.F.; Brink, E.J.; Meijer, G.W.; Prince n, H.M.; Ntanios, F.Y. Safety of long-term \nconsumption of plant sterol  esters-enric hed spread. Eur. J. Clin. Nutr.  2003 , 5, 681\u2013692. \n165. Gylling, H.; Puska, P.; Vartiainen, E.; Mietti nen, T.A. Retinol, Vitamin D, carotenes and \n\u03b1-tocopherol in serum of a moderately hyperc holesterolemic population consuming sitostanol \nester margarine. Atherosclerosis  1999 , 145, 279\u2013285. \n166. Noakes, M.; Clifton, P.; Ntanios, F.; Shrapnel, W.; Record, I.; McInerney, J. An increase in dietary \ncarotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid \nconcentrations. J. Clin. Nutr.  2002 , 75, 79\u201386. \n167. Weing\u00e4rtner, O.; B\u00f6hm, M.; Laufs, U. Controversial role of plant st erol esters in the management \nof hypercholesterolaemia. Eur. Heart J.  2009 , 30, 404\u2013409. \n\u00a9 2013 by the authors; licensee MDPI, Basel, Switzer land. This article is an open access article \ndistributed under the terms and conditions of  the Creative Commons Attribution license \n(http://creativecommons .org/licenses/by/3.0/).", "start_char_idx": 0, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"0bfc066a-ba86-40ed-8104-6d4beb6f2d85": {"node_ids": ["1d7fa982-ab9a-49cc-ba8b-0896cb97ac4f"], "metadata": {"file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\notes.txt", "file_name": "notes.txt", "file_type": "text/plain", "file_size": 8, "creation_date": "2024-05-17", "last_modified_date": "2024-05-15"}}, "1107ab99-664b-48a5-b94f-ea9025bf18b8": {"node_ids": ["f5adf13f-1fa8-4204-8071-95b0da32d2cb"], "metadata": {"page_label": "1", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "a8717909-0907-4df6-b12a-c03d0343fd63": {"node_ids": ["e54c4926-6c1f-443c-9d9a-a4ae99e52c97"], "metadata": {"page_label": "2", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "cc38eaa8-ce72-49e3-b971-e7dc10b40b27": {"node_ids": ["44b0e9a1-69ef-406b-ae06-ccf611d55b4f"], "metadata": {"page_label": "3", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "892bb4b6-097f-4f5e-ac43-46cad64c9f8e": {"node_ids": ["a5b23d14-b435-462f-903a-34952df58eb9"], "metadata": {"page_label": "4", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "2b757389-852c-42b7-8b22-598cab104548": {"node_ids": ["d4ce7d22-4984-4c75-a490-d1ca64b21d19"], "metadata": {"page_label": "5", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "f0dcae12-7262-4bd1-b26d-8949e0dd23ff": {"node_ids": ["f1a11274-4d35-4b79-a6da-9535a1e603a7"], "metadata": {"page_label": "6", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "4416187a-48b2-4ba2-ba33-967b7851d49c": {"node_ids": ["adbfc440-86ec-4ae7-a37c-ff6ef7c8c5a4"], "metadata": {"page_label": "7", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "a7311867-ad05-4682-86c6-aa0979a2a0fd": {"node_ids": ["967333ad-71af-4763-971e-b9fecbed34db"], "metadata": {"page_label": "8", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "103eab7d-0c6d-4ac8-86dc-b6efcbc69614": {"node_ids": ["2fa43eaf-a5c2-41b0-8cc3-212e3c63b027"], "metadata": {"page_label": "9", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "5133dbb4-b887-4acd-a401-e7625d9a4773": {"node_ids": ["01dda873-d2f0-4d4f-9b40-097ec6ef9a4a"], "metadata": {"page_label": "10", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "e9add9a4-05a6-40de-8b34-253eabc8f98e": {"node_ids": ["070f60c4-5bff-4f3c-91ff-9d0df379d2c2"], "metadata": {"page_label": "11", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "b2f4a49f-f2bc-4159-9ed4-1ce70bf7a418": {"node_ids": ["62385a64-e0d9-4506-80c4-3ff712ef0f31"], "metadata": {"page_label": "12", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "da442196-2381-49b8-90ce-0d40bfe337bf": {"node_ids": ["8a074b39-5841-4264-8f48-1be7c0c91348"], "metadata": {"page_label": "13", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "a116771d-514d-4b60-8024-d3503a4638ae": {"node_ids": ["e1ce8045-808b-4cf6-9254-c5a3e1e5176a"], "metadata": {"page_label": "14", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "75ec51b9-be27-434e-b6df-d9f261ca2253": {"node_ids": ["46332af2-7ced-4675-9b08-b230b898202e"], "metadata": {"page_label": "15", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "076164f0-a19f-4bde-9daa-2d063ab87c93": {"node_ids": ["4e0610a2-607a-43d7-84c8-c7a1afd961ac"], "metadata": {"page_label": "16", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "ed305f47-a111-4fe0-a483-79212d988b65": {"node_ids": ["bbcde0a7-6aac-4fca-bee5-f240a7847d5e"], "metadata": {"page_label": "17", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "9d035547-2b01-4fd6-936a-7a1f11fbb0c5": {"node_ids": ["c663f792-051a-418d-9568-d1c427515f74"], "metadata": {"page_label": "18", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "c908c086-bda0-45ae-b975-e2a4e5192787": {"node_ids": ["c4dbfff4-40a6-4636-a304-3653b5b3a892"], "metadata": {"page_label": "19", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "a9dbf832-4334-4668-ab56-7c9c889a92c0": {"node_ids": ["b98b919b-f0b5-46fc-92ee-b58412bdb893"], "metadata": {"page_label": "20", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "2de40199-8596-47f5-8203-98e24286a7c7": {"node_ids": ["6aefacea-a52e-4e93-a138-815c45a2aac9"], "metadata": {"page_label": "21", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "595d2b25-1048-4cda-8533-b59b1768ec7c": {"node_ids": ["3b1d6d1b-6f1e-4b10-b9ae-5d8d20868c39"], "metadata": {"page_label": "22", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "2abe2a1d-9183-4862-864a-f2fc074aed8d": {"node_ids": ["c3b3edaa-8624-4d94-bd78-628d5f5e3443"], "metadata": {"page_label": "23", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "f0d1f3f5-6bbf-43bb-a474-bbc09a4335bf": {"node_ids": ["3593cd51-54ef-4a72-9632-0183a9c3a728"], "metadata": {"page_label": "24", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "9764b622-a0f5-455f-86b2-448bccb6f9c8": {"node_ids": ["3d00c419-4793-4f26-90f3-d1c6904a0287"], "metadata": {"page_label": "25", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "07168dc4-6b65-4ea3-bcba-263687653332": {"node_ids": ["fa4c8e04-9869-4cfa-8f8c-69c4f2491505"], "metadata": {"page_label": "26", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "5adf154b-4e1e-40c6-9f46-002e60ddc559": {"node_ids": ["8673c0e3-8c3c-44fd-bc35-4d1179863d4c"], "metadata": {"page_label": "27", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "14061b51-3fd6-463c-9b1d-53a4e0bf6fb4": {"node_ids": ["a23d123d-75c1-4a8e-b33c-d5398a638145", "e085de5d-e30a-4739-ade6-6bb8d0f177e4"], "metadata": {"page_label": "28", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "eaa8a52f-a714-4d3e-a134-1c2cc2e39422": {"node_ids": ["5d542be2-6f5d-448b-82a6-e3e10732d220", "fff735ed-980d-4e5e-99ef-af941774cdd2"], "metadata": {"page_label": "29", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "7b80ed4a-affa-4944-9bea-8d3cba483d10": {"node_ids": ["13a862ea-68ca-4d49-8bd2-cdc6ef44f8b7", "fd01ca2e-63ac-4ad3-bd77-8b252be795be"], "metadata": {"page_label": "30", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "9591e85f-fd5b-462c-8b35-c4874f654bde": {"node_ids": ["5bf2922c-9507-4f0d-a216-3fdd02f1b18b", "d627cb46-b3e3-4775-972d-33c028defa61"], "metadata": {"page_label": "31", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "89305721-b50d-458c-b539-8f3b5feed0bd": {"node_ids": ["be28483e-f94b-4a92-8061-d2d85e44b838", "82d8c799-fac4-4de5-bb8d-b19d86b6805a"], "metadata": {"page_label": "32", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "56bf0e33-4e80-4fac-9b8f-1a418d45563e": {"node_ids": ["bd1039e8-478d-4bec-a205-27df6fe0de3d", "dbbd5846-5753-4572-942e-3b31727de57d"], "metadata": {"page_label": "33", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "e52504b3-5057-47b9-a518-b38c93c085d7": {"node_ids": ["36ad5525-4bea-4787-8b4b-7e48b21d4159", "07b742ad-2db3-4264-adeb-eedee52dcd91"], "metadata": {"page_label": "34", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "b87b2a23-5be1-465a-8db3-ee1221937513": {"node_ids": ["67f8569b-d127-4360-81bc-6456452f0cf9", "8ddf7af6-435b-4257-9022-8363dfe93cd2"], "metadata": {"page_label": "35", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "4b30fa72-0d96-4d4c-8501-338f0fbff9c5": {"node_ids": ["c5c03a8b-8f7a-4b65-918a-3716365e8529", "5c4fa3c0-3c38-4ff1-9d1d-f37950055f36"], "metadata": {"page_label": "36", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "59bba3f0-274c-4ade-8538-fd0e28432ab1": {"node_ids": ["4225d9ac-4cad-4a20-8a7e-21531a6d6063", "bec8d9b0-9048-4088-ba4f-b043fd710713"], "metadata": {"page_label": "37", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}, "437a834a-0cb4-4c5a-b986-2e608c16e623": {"node_ids": ["68983b9b-6c16-4a4d-a5a2-8d4ee617a21a"], "metadata": {"page_label": "38", "file_name": "pdf1.pdf", "file_path": "E:\\DESKTOP\\RapidLabs\\Llama_chatbot\\data\\pdf1.pdf", "file_type": "application/pdf", "file_size": 359016, "creation_date": "2024-05-17", "last_modified_date": "2024-05-07"}}}}